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                                                        Abstract 
Parasitic helminth infections of livestock are a threat to the health and production of 
livestock, crops and to human health. One third of the world’s animal population was 
affected in 2015 by helminth infestations causing severe morbidity. The shortfall of 
new drugs against nematode parasites and the resistance hazard represents an 
urgent need for the development of novel anti-parasitic drugs with effective delivery to 
the target site. It is hypothesised that the toxic efficacy and selectivity of anthelmintic 
drugs can be improved using prodrug forms that possess intracellular drug targeting 
moieties that can circumvent resistance mechanisms.  
A series of novel targeted anthelmintic candidate drugs have been synthesized, based 
on a colchicine (Col) core; code-named: AM1 (Col-prolinol), AM3 (Col-4-
hydroxypiperidine), AM4 (Col-(R)-3-pyrrolidinol), AM5 (Col-Boc-aminopyrrolidine) and 
AM6 (Col-aminopyrrolidine), these compounds are broadly tubulin targeting amino-
colchicine derivatives. Amino-colchicines were then conjugated with a lipophilic, 
cationic targeting moiety TPP (triphenylphosphonium) ion that has potential to bypass 
resistance and achieve selectivity by direct and fast accumulation in the matrix of 
mitochondria. Novel prodrugs AM2 (Col-prolinol-TPP), AM7 (Col-aminopyrrolidine-
TPP), AM8 (Col-4-hydroxypiperidine-TPP), AM9 (Col-(R)-3-pyrrolidinol-TPP) are 
ester-linked triphenylphosphonium butanoyl (TPP) conjugates of amino-colchicines 
AM1, AM6, AM3 and AM4 respectively that are designed to not only pass through cell 
membranes and localise in the mitochondria but also facilitate drug cellular uptake by 
avoiding p-glycoprotein-type mediated efflux mechanisms. All novel compounds have 
been characterised by high resolution mass spectrometry and 1H and 13C NMR 
spectroscopy. Preliminary biological evaluation of AM1 and AM2 was carried out by 
treatment of the C. elegans non-parasite model organism. Results demonstrated that 
AM2 (100µM) showed significant toxicity against C. elegans at an incubation time of 
22h. Physicochemical properties of these novel agents has been described in terms 
of distribution coefficient log D values, that showed they are lipophilic in nature and 
should have the ability to cross lipid bilayers and mitochondrial membrane. Preliminary 
molecular docking studies also demonstrated binding affinity of AM6 (Col-
aminopyrrolidine) with tubulin. These novel prodrugs have the potential to be 
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The principal aim of this project is to design & develop novel targeted anthelmintic 
amino-colchicine prodrugs that can deliver the active drug inside mitochondria (target 
site), by the use of lipophilic, cationic drug delivery vehicle; TPP (Triphenyl 
phosphonium cation) to achieve selectivity and toxic efficacy of these agents. These 





It was hypothesised that by the help of TPP, triphenyl phosphonium which is a 
lipophilic, delocalised cationic carrier molecule, drugs can be directed to the target 
sites (mitochondria) by potentially bypassing the resistance mechanisms and in doing 
so it will achieve maximum efficacy and decreased general toxicity to the host.  
Drug molecules conjugated to TPP with a specific linkage (such as an ester or amide 
linkage) designed to be cleaved by esterase or peptidase in the host to release active 
drugs at the site of action. The negative membrane potential of cell and mitochondrial 









Helminth is a Greek word meaning “worm”, helminths infested humans, animals, and 
crops before our earliest written history. Thousands of years ago eggs of intestinal 
helminths were found in mummified human faeces (Lindquist and Cross, 2017). 
The course of the modern twentieth century world was altered markedly by the same 
kind of helminths. In China, during the cold war, schistosomes that were known as “the 
blood fluke that saved Formosa” sickened troops of Mao causing acute 
schistosomiasis (Kreston, 2014). A study tells that helminths infect approximately one 
third of the world’s population (Besier et al., 2016; Hotez et al., 2006) and can have a 
significant effect on disease in farm animals (Roeber et al., 2013). 
 Categorisation of helminths 
 
Helminths include invertebrates and are categorised on the basis of their general and 
external shape, the organs of host they reside in, egg morphology and larval or adult 
stages. There are two forms of helminths namely; bisexual and hermaphroditic.  
There are two main phyla of helminths: 
1) The nematodes (known as round worms): this phylum includes major intestinal 
worms also called soil-transmitted worms and the filarial worms that cause filariasis 
(Hotez et al., 2006). 
2) The Platyhelminths (known as flat worms): this phylum includes the flukes (also 
called as trematodes), such as Schistosomes and the tapeworms (also known as 






Table 1. 1. Showing important helminths, their transmission routes and mode of entry (Castro, 1996). 
Parasite Transmission Entry route 
Roundworm 
Enterobius vermicularis (pin 
worm) 




Eggs, direct faecal 
contamination  
Eggs matured in soil 
Eggs matured in soil 








Taenia solium (pork tapeworm) 
Taenia saginata (beef 
tapeworm) 
Echinococcus granulosus  
 
Larvae in infected pork 
Larvae in infected beef 
 

































 Anatomical features of Helminths 
 
Nematodes and platyhelminths share the same anatomical features that are 
necessary for inhabiting the host. The outer layer of helminths is called the tegument 
in platyhelminths or the cuticle in nematodes (Richardson and Smaill, 1998). Flukes 
or trematodes are leaf shaped worms, they are mostly hermaphrodites (genderless 
that means having sex organs of both sexes in the same individual hence both self 
and cross fertilisation occur) with the exception of blood flukes, Schistosoma species 
(that have both male and female separate sexes but live in pair as male and female 
schistosomes or fluke) (Halton, 2004). Tapeworms or cestodes are hermaphrodites. 
Adults reside in the intestinal lumen of host whereas larval forms live in extra-intestinal 
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tissues of the host. They have segmented bodies and are elongated in shape (Castro, 
1996; O’Connell and Nutman, 2016). 
Roundworms or Nematodes are bisexual worms that are cylindrical in shape. Both 
adults and larval forms reside in intestinal and extra-intestinal tissues of host (Gasser 
et al., 2016). 
 
 Parasitic Helminths a threat to humans, livestock & crops 
 
Norman Stoll (1947), made a worldwide estimation about the number of people 
infected with parasites in his research entitled  “the wormy world” (Stoll, 1999). 
According to a recent estimation approximately one-third of the almost three billion 
people of Asia, Africa, America and others are infected with some kind of parasite 
(Horton, 2003). Diseases caused by helminths are the most neglected tropical 
diseases (NTDs) in the list of the top seventeen neglected diseases issued by WHO 
(McCarty et al., 2014). All of these diseases are linked with poverty levels in that 
region. According to one study, more than one billion people are suffering from one of 
the NTD (Kyelem et al., 2011). 
The most prevailing diseases in NTDs are the ones caused by helminths. Parasitic 
helminths often have long life and their reproductive rate is very high. This would mean 
that treatment employed to control the helminth infection can only be effective if they 
have the ability to produce long term sustainable effects (Tchuem Tchuenté, 2011). 
Every year, due to parasitic diseases in sheep and cattle, there are estimated financial 
losses of 1 billion dollars in Australia (Roeber et al., 2013). In UK, nematodes; 
Haemonchus contortus, Teladorsagia circumcincta and trematode Fasciola hepatica 
are economically the most important helminths that cause infections in sheep, goats 
and cattle (Papadopoulos et al., 2012). Fasciola hepatica, a liver fluke, infects 300 
million cattle and 250 million sheep throughout the world and costs financial losses of 
3 billion US dollars a year. In some parts of the UK, 1 in 3 cattle and 1 in 5 sheep are 
infected with liver fluke (Fairweather and Fairweather, 2005). Helminths infections of 
livestock cause serious economic losses worldwide specifically parasite nematodes 




Amongst helminth infection, gastrointestinal infections such as: ascariasis, 
strongyloidiasis, fascioliasis and trichuriasis are of primary importance and affect more 
than one billion human population (McCarty et al., 2014). In 2010, a study was 
conducted on the prevalence of helminths infection, demonstrating that 807-1221 
million people affected by Ascaris lumbricoids, Trichuris trichiura infected 604-795 
million people population and hookworm infected 576-740 million population of 
humans. An annual loss of 118 billion dollars has been estimated which is a result of 
compromised crop population due to nematode infestation (Howard J Atkinson et al., 
2012). 
According to Nicol et al., 2011 he production losses in crops are more than 14.6% in 
developing countries because most of developing or under developed countries are in 
tropical and sub-tropical regions where helminths infections are most prevalent. This 
is due to climate factors i.e. warm and humid environment that is in favour of helminths 
growth and survival, so more helminths mean more damage to the crops and less 
production.  
 
 Gastro-intestinal Nematodes 
 
Among all helminths gastrointestinal nematodes are the major worm infections  that 
effect both small and large ruminants, for example; sheep, goats, and cows in the 
whole world (Roeber et al., 2013). The main gastrointestinal nematodes belong to 
order Strongylida family trichostrongylidae (Papadopoulos et al., 2012). The most 
economically important nematode in order strongylida includes Haemonchous 
contortus and Teladorsagia circumcincta (Gasser et al., 2016). PGE (parasitic 
gastroenteritis) (Figure 1.1) is the most prevailing gastro-intestinal disease in Scotland 
caused by T.circumcincta (a nematode) damaging livestock production efficiency 






                                 Yearly increase in PGE infection in cattle & sheep 
Figure 1. 1 Shows % of diagnosable submission of cattle and sheep in the Vet. Hospital of Scotland 
with PGE (parasitic gastroenteritis) yearly (Wilson et al., 2008). 
 
 Life cycle of Strongylida nematodes 
 
In the order strongylida, adults are dimorphic and reside in the digestive tract, where 
females lay eggs in large numbers. Those eggs are expelled from the body of the host 
through faeces (Gasser et al., 2016). 
Eggs are 70-150 µm in diameter and take 1-2 days for hatching. After hatching, larvae 
feed on bacteria and finally develop into 3rd stage ensheathed larvae (L3s) in the soil. 
The sheath represents a cuticular layer that protects L3s from harsh environment. 
Animals are infected when they ingest L3s stage of larvae, when L3s pass through the 
stomach of a ruminant, they lose their protective sheath and undergo a tissue phase 
before their transition to L4 stage or pre-adult stage (Levine, 1980) (Figure 1.2). 
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Figure 1. 2 Shows life cycle of gastrointestinal nematodes of order strongylida in small ruminants 
(Peebles, 2007). 
 
At the end of the grazing season when conditions became unfavourable the larvae go 
through a phase of halted development called “hypobiosis”. This is common in H. 











 Introduction to Anthelmintic drugs: 
 
Anthelmintic, nematicide or wormer (also known as dewormer or drench), is a 
chemical or drug that is used to treat infectious diseases caused by parasitic helminths 
including round worms (nematode) and flatworms (trematodes and cestodes) (Table 
1.2).  
 
Table 1. 2. List of registered drugs for the treatment of parasitic worms’ infections in human (Greenberg, 
2005; Pharmaceutical Journal, 2019).  
Schistosomiasis (blood fluke) Intestinal round worms 
Oxamnaquine Piperazine 
Praziquantel Benzimidazoles 
  Morantel 
  Pyrantel 
Cestodiasis (tape worm) Levamisole (LEV) 
Albendazole Avermectins (AM) and milbemycins 
Niclosamide Tribendimidine 
Benzimidazoles (BZ)   
Praziquantel   
Fasciolasis (liver fluke) Filariasis (tissue round worms) 
Triclabendazole Diethylcarbamazine 
  Albendazole 







 Classification of Anthelmintic Drugs 
 
Classification of these agents are based on similarities in chemical structure and 
mechanism of their actions. 
1.2.1.1 Piperazine 
 
Piperazine was used for the first time in 1950 as an anthelmintic drug and is still being 
used as active component of many remedies used for the thread worm infection in 
children and available as over the counter (OTC) drug. Piperazine was first studied on 
nematode Ascaris suum, where it produces flaccid (a reversible paralysis of belly 
muscles) by acting on GABA receptors as a GABA mimetic agent (Fennell et al., 
2008). R. J. Martin, 1997, investigated the mechanism of action of piperazine in 
Caenorhabditis elegans (C. elegans) and its activity was compared between wild and 
mutant gene (unc-49). They showed piperazine has the same inhibitory effect on both 
wild and mutant gene not only in a C. elegans developing assay but also in intact 
animals containing both genes (Table 1.2) (Figure 1.3).  






Figure 1. 3 The chemical structure of piperazine. 
 
1.2.1.2 Benzimidazoles (BZ) 
 
Benzimidazoles (BZ) are broad spectrum anthelmintic drugs. Thiabendazole and 
Albendazole are the primary drugs in this class (Table 1.2). Thiobendazole was the 
first member of this class and was discovered in 1961 and several benzimidazoles 
(BZ) were discovered after that. A massive literature demonstrated that their efficacy 
is because of their selective binding with β-tubulin and as a result they interfere and 
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jeopardise microtubule cytoskeleton formation (Figure 1.4) (De Nollin and Borgers, 
1975; Lacey, 1988). 





Figure 1. 4 Chemical structure of benzimidazole. 
 
1.2.1.3 Imidazothiazoles and tetrahydropyrimidines 
 
The most widely used imidazothiazole is levamisole (LEV) (Figure 1.5) and tetrahydro 
pyrimidines pyrantel and morantel are in widespread use. These compounds are very 
active against nematodes but happen to have no effect on trematodes and cestodes 
whatsoever. Levamisole is derived from the compound tetramisole which is a racemic 
mixture of D and L isoforms, whereas levamisole is purely an L-isomer. Pyrantel and 
morantel are from the class tetrahydro pyrimidines and have a similar structure. They 
both are very effective anthelmintic drugs (Hausen et al., 2011; Scorza et al., 2006). 
Both agents act as agonists of nicotinic receptors and cause paralytic spasticity on 
helminths’ muscle wall by activating excitatory acetylcholine nicotinic receptors 
(nACRs) (Scorza et al., 2006). 
 





Figure 1. 5 Chemical structure of levamisole (LEV). 
 
Levamisole also causes spastic paralysis in Caenorhabditis elegans specifically in egg 
laying worms. It is even more potent as compared to acetylcholine itself and exerts its 
activity at lower µM concentration than acetylcholine (Ruiz-Lancheros et al., 2011). 




1.2.1.4 Macrocyclic lactones: avermectin (ivermectin) 
 
In 1980, Merck introduced ivermectin for the first time. Ivermectin is a semi-synthetic 
derivative of avermectin (AM) (a macrocyclic lactone) which is formed as a 
fermentation product of the microbe Streptomyces avermitilis (Howard, 2011). 
Ivermectin induces a very intense and prolonged paralysis effect on pharyngeal and 
body wall musculature (Römbke et al., 2010). It interacts with acetylcholine gated 
chloride channels, acetylcholine receptors and glycine receptors. Most importantly it 
has high affinity for glutamated chloride channels that defines its anthelmintic activity 
in nematodes (Guggisberg et al., 2014; Pemberton et al., 2001).  
 
 Limitations of Anthelmintic or Nematicide or Dewormer 
 
Efficacy of anthelmintic drugs is in danger considering their long-term usage, incorrect 
handling of these agents and under dosage. All these factors can influence on their 
efficiencies and play a significant role in emergence of resistance against these agents 
(Nielsen et al., 2014). Another factor that can contribute to their limitation, is 
unavailability of these drugs in the affected area, because of economic reasons or 
dearth in veterinary facilities. Especially in most part of tropical regions animal dies 
due to haemonchosis either acute or chronic and loose massive body weight that can 
be another constraint in the poor performance of ruminants in meat production 











Table 1. 3  List of some recommended drugs against haemonchosis in sheep (Kaplan, 2004; Kaplan, 
2014). 
Chemical group Anthelmintic Prescribed dose 
Imidazothiazoles Levamisole (LEV) 7.5 mg/kg  
Benzimidazoles (BZ)   Albendazole 
Fenbendazole      










Salicylanilides Closantel   10 mg/kg 
 
The mainstream anthelmintics are limited in their action between nematodes, cestodes 
and trematodes such as, praziquantel (Table 1.2), an anti-parasitic drug used for 
cestodes and trematodes infections in human, is completely useless against 
nematodes. Benzimidazole (BZ) is the only class of anthelmintics that possess cross-
phyla efficacy but has shown more activity against nematodes than other phyla (Table 
1.3) (Campbell, 1990). Moreover, for the crop protection from helminth infestation, use 
of nematicide or dewormer should take into consideration the stability of agent, 
leaching in the soil and ecotoxicity (environmental toxicity) (Prichard et al., 2012). 
Ivermectin has been the most successful anthelmintic both in tropical diseases and 
veterinary medicine and a saviour drug in most parts of Africa where its consumption 
has changed the lives of populations that were previously confounded by 
Onchocerciasis (a tropical ailment), commonly called river blindness. However, 
resistance was developing against this drug according to the published researches 








 Microtubules (MT)  
 
In the 19th Century Flemming explained that there are two components in a eukaryotic 
cell that undergo mitosis and those are: chromo elements or chromosomes and thin 
filaments called microtubules (MT) (Tansatit et al., 2006). It is known by the analysis 
of different mutation in the microtubules cytoskeleton that a slight change can lead to 
functional deformity in the cell and organism itself (Janke, 2014). 
 
 
 Microtubules Organisation 
 
Microtubules (MT) are a set of 25nm wide tubes that are hollow from inside. These 
tubes are made by sidelong interplay of 13 protofilaments and each protofilament in 
turn composed of heterodimers of α and β tubulin which interact head to tail to form 
these protofilaments. Alpha (α) and beta (β) tubulin are two closely related isoforms 
that bind GTP. This molecular organisation describes the polarity of microtubules. At 
one end only α-tubulin exposes and is also called the minus end, and on the other end 
only β-tubulin exposes called the “plus end” (Figure 1.6) (Akhmanova and Steinmetz, 
2015; Curcio and Bradke, 2015). 
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Figure 1. 6 Organisation of MT in a eukaryotic cell, showing tubulin dimers, protofilaments and 
catastrophe switch (Akhmanova and Steinmetz, 2015). 
 
MTs can grow and shrink in the presence of GTP and it can go between these two 
phases by catastrophe switch (Gardner et al., 2013; Lacey, 1988). Microtubule 
catastrophe is an event that manifest itself by a sudden switch between a growing 
stage and a rapidly shortening stage of microtubule in which MT growth interrupted by 
occasional switching to rapid shrinkage (or “MT catastrophe”) and then switching back 
from shrinkage to growth (“called rescue”) (Figure 1.6). The reason behind this 
catastrophe is either a single random event that happen due to sudden loss of MT 
protecting end or may consist of multi-process event (Gardner et al., 2013). Mitchison 
and Kirschner, (1984) first described this microtubule (MT) instability in 1984. They 
demonstrated that all these events happen at the plus end (positive end) and that the 
negative or minus end is more stable (Horio et al., 2014). Microtubules are essential 
for cell division which is key for life if anything happened with assembly and 
disassembly of microtubules that can be lethal, or it can produce cells with a wrong 
number of chromosomes. The condition with abnormal number of chromosomes 
(either gain or lose) is called aneuploidy and is a main cause of miscarriages, 




 – Microtubules as target molecules in antiparasitic treatments 
 
Microtubules are the promising biological target for many small molecules because of 
its dynamic role in cytoskeletal organisation and cell functions. An important class of 
anthelmintic agents called benzimidazoles (BZ) (1.2.1.2) (Figure 1.4) binds with one 
of protein subunit of microtubule called β -tubulin causing unfolding of the protein 
leading to abnormal conformation that further inhibit polymerization of α- and β-tubulin 
subunits to form microtubules, this results in a lethal effect in rapidly dividing cells of 
helminth. BZ bind with 25-400 folds greater inhibition constant with nematode tubulin 
as compared to mammal’s tubulin (Maddison et al., 2008). 
Colchicine which is a spindle poison and used as a main drug component in this 
research shares the same binding site as with the benzimidazoles (an anthelmintic 
drug), it shows a strong binding affinity with tubulin and binds at the interface of α and 
β tubulin by forming a colchicine-tubulin complex that depolymerises microtubule 
organisation (discussed in detail under 1.4.4.2.1).  
 
 Microtubule Targeting Strategies 
 
Microtubules have highly dynamic properties that are mandatory for the spindle 
assembly function. But at the same time, they can also make mitotic cells very 
sensitive and a potential target for the chemotherapeutic agents or factors that can 
change their properties. Microtubule targeting agents (MTA) or tubulin binding agents 
(TBA) can alter dynamics of MT so it made tubulin a very important target in cancer 
therapy and they were used as pioneer chemotherapeutic agents in cancer therapy. 
There are several TBA exist that are extracted from wide range of species such as 
plants, sponges and bacteria. Tubulin binders or inhibitors are also knowns as “spindle 
poisons” or anti-mitotic compounds, because they halt mitosis by inhibiting spindle 
formation or cause disruption in spindle assembly (Jordan and Wilson, 2004). All these 
microtubule targeting agents work on one of these principles i.e. they either promote 
microtubule stabilisation or they mimic destabilisation of microtubules. The 
predominant idea behind employment of MTA as anti-cancer agents came from their 
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ability to interfere with mitotic cell division that occurs in cancer cells all the time. 
(Parker et al., 2014). However, there is still the need of discovering novel ways to 
target microtubules or tubulin that can outweigh the ability of cancer cell to become 
resistant towards therapeutic effects of drugs.  
 
 Targeted delivery of tubulin binders 
 
Tubulin binders have no selectivity for the dividing cells so can lead to off-target effects 
and general toxicity (Parker et al., 2014). For achieving maximum efficiency and to 
overcome the problem of toxicity, Elena et al., (2013), designed library of tubulin 
binders that are modified and synthesised in conjugation with fluorescent probe to 
achieve imaging of tubulin molecule.  They demonstrated that modification in existing 
tubulin binders by conjugation, these compounds can modulate microtubule dynamics 
or its function. They used thio-colchicine, cephalomannine and paclitaxel as tubulin 
binders and employed FITC (fluorescein isothiocyanate) for the conjugation purpose 
to make a fluorescent probe for MT imaging (Riva et al., 2013). Passarella et al., 
(2009), proposed that histone deacetylase (HDAC) inhibitors are potential anti-cancer 
agents because of their ability to inhibit cell proliferation and induction of apoptosis. 
These agents enhance the acetylation of histone so as a result they reverse the 
epigenetic changes occurs in cancerous tissue. Also, these inhibitors modulate 
acetylation of non-histone proteins such as alpha-tubulin. On the basis of this finding 
they proposed by combining both tubulin binder and HDAC inhibitors there will be a 
synergistic effect. This hypothesis was also demonstrated by Itoh, et al., (2007), where 
they employed thiocolchicine and paclitaxel with HDAC inhibitor and the final product 
showed synergism. 
 
 Binding sites of tubulin binders 
 
Tubulin binders bind at various binding sites on tubulin. Some tubulin poisons bind at 
beta-tubulin, some bind at alpha-tubulin and some bind at the interface of alpha and 
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beta dimers. Beta tubulin has 3 conventional binding pockets, these include colchicine-
binding sites, taxol or paclitaxel binding site and vinca-alkaloid binding site.  
 
 Tubulin Binding Agents (TBA’s) 
 
Tubulin binders divided into 2 classes depending on their effect on microtubule 
dynamics.  
1.4.4.1 Microtubule Stabilising Agents 
Taxol (paclitaxel), docetaxel and taxanes are in this category. These are natural 
agents and obtained from the bark of Taxus brevifolia. Taxanes use against solid 
tumours for example breast, prostate, lungs and ovarian cancers. They bind to beta-
tubulin and stabilise MT. Microtubule targeting agent epothilone B analog ixabepilone 
(product of myxobacterium sporangium cellulosum was approved by FDA for 
advanced breast cancer. It binds on into the taxol binding site and stabilise MT 
assembly in a similar way as paclitaxel (Rodriguez-Garcia et al., 2017). 
1.4.4.2 Microtubule destabilising agents 
This category includes Vinca alkaloids that are extracted from Catharanthus roseus, it 
includes compounds like; vincristine, vinblastine, vindesine, vinorelbine and vinflunine. 
They are active against a variety of solid tumors and lymphatic cancers. (Waight et al., 
2016). The second most important class of destabilisers include agents that bind on 




Colchicine is the primary drug in this class. It is one of the oldest prescribed drugs that 
has been and still being used in the treatment of gout and FMF (familial Mediterranean 

























Figure 1. 7 Chemical structure of colchicine showing three rings: A (6 membered ring), B (7-membered 
ring) and C (7-membered ring).  
 
FDA in 2009 has approved colchicine as a medication for gout and FMF (Yang, 2010). 
Colchicine is obtained from a natural source, “Colchicum autumnale” (Colchicaceae), 
the meadow saffron, and other species called “Gloriosa superba”. Colchicine is a 
spindle poison that binds to tubulin with strong affinity at the interface of alpha & beta 
tubulin and forms a tubulin-colchicine complex, depolymerises the microtubule by 
acting as a disrupting agent and mediate mitotic arrest and cell death (Bhattacharya 
et al., 2016; Nepali et al., 2016). Abnormal increase in mitosis rate is one of the most 
significant and well-studied feature of cancer cells. This feature makes them so 
vulnerable against microtubule targeting agents (MTA’s), because microtubule (MT) is 
part of cytoskeletal and establishes the dynamics of spindle apparatus moreover 
comprises the main elements of mitosis cell division. Any agent that destabilises the 
MT will eventually halt the mitosis process.  
Colchicine, that inhibits the MT polymerization, causes perturbation of both 
microtubule spindles and mitosis (Bhattacharya et al., 2016; Rodriguez-Garcia et al., 
2017). The application of colchicine in cancer therapy is limited due to its cytotoxicity 
in the non-cancerous or normal cells of the body. Oral colchicine is safe when 
administered in safe proper clinical dose. A recent study demonstrated that colchicine 
can produce autophagy and premature senescence in human lung cancer cells when 
administered in safe clinical dose. Experiments showed that colchicine inhibited 
proliferation in A549 (human lung carcinoma cell line) in a concentration gradient 
manner. A 17% loss in viability of cancer cells was monitored when incubated for 96 
h in a cell viability assay. Study further reported that colchicine produced ROS 
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(reactive oxygen species) that was responsible for induction of autophagy 
(Bhattachariya et al., 2016). 
 
 Novel Example of Tubulin Binders 
 
BAL27862 (Figure 1.8) is a very potent inhibitor of cancer cell growth and it promotes 
apoptosis in cancer cells. It showed potent activity in cancer cells that were resistant 
to conventional MTA’s (microtubule targeting agents) taxanes and vinca alkaloids 
(Moudi et al., 2013). Studies demonstrated that this new drug Bal27862 inhibits MT 
production by interfering with microtubules organisation and its dynamics within the 
cell (Bachmann et al., 2015). A study by Andrea Porta (2014) demonstrated MOA of 
this novel drug. Study showed Bal27862 is a potent MTA that binds at the colchicine 
binding site (CBS) on tubulin molecule and exert significant effect on MT organisation 
in a cell (Prota et al., 2014).  






















The biggest issue with the existing anti-parasitic drugs is emerging resistance against 
them (Lalchhandama and Lalchhandama, 2010; Ramos et al., 2018). Resistance is 
the major problem when it comes to efficacy of anthelmintics and a hazard in 
sustainability of the UK’s farming, animal welfare and agriculture income (Peebles, 
2007) (Table 1.4). 
Research showed that parasites are becoming resistant to antiparasitic drugs 
(Lalchhandama, 2010) and posing a great threat to global food security by affecting 
goat and sheep farms all across the globe (Brophy et al., 2012; Ray M Kaplan, 2004). 
For example, Haemonchus contortus, which lives in the stomach of ruminants, has 
shown resistance against many anthelmintics available on the market, consequently 
causing great economic losses (Howard J Atkinson et al., 2012). Nematodes that are 
resistant to the anthelmintic represent serious problems in small ruminants (sheep and 
cattle) due to their specialised stomach (Wolstenholme et al., 2004). In Australia the 
profitability of the whole sheep industry has been threatened by severe prevailing 
resistance (Besier and Love, 2003) (Table 1.4). Epe and Kaminsky in 2013, discussed 
in detail the introduction, usage and limitation of 3 new anthelmintic agents namely; 
emodepside by the brand name profender, tablets for dogs and spot-on for cats, 
monepantel (zolvix for sheep), derquantel (for sheep) (Epe and Kaminsky, 2013) .  
Resistance has developed against all the major classes of broad spectrum 
anthelmintics such as benzimidazoles (BZ), avermectins (AM) (that includes 
ivermectin, moxidectin and doramectin), milbemycins, levamisole (LEV) and other 
nicotinic agonists. Moreover, anthelmintics of narrow-spectrum activity such as 











Table 1. 4. Some examples of drugs to which resistant strains of Haemonchous contortus were reported 
in different countries (Getachew  et al., 2007). 
Continent Country Anthelmintic 





Tetramizole                             
Ivermectin     
Almost all groups                                                                                        
Europe France 
 
Great Britain         
Benzimidazoles                                     
Levamisole 
Benzimidazoles                               




South America      Argentina   
 
 




Benzimidazoles                                      
Levamisole 
Ivermectin                        
Australia Australia  Avermectin 
 
In the past two decades, triclabendazole (TCBZ, a member of BZ) has been the 
primary choice to treat liver fluke infections in livestock because of its extraordinary 
activity against migrating stages of fluke (Fairweather and Fairweather, 2005) but 
resistance is developing. The first report of TCBZ resistance was in Australia, 1995. 
Later, it was reported in England, Ireland, Scotland, southwest Wales, the Netherlands 
and Spain. In 2003, in the UK, the season was reported as the worst especially in 
Scotland and northern England, due to dramatic renaissance of fasciolosis and a 
record number of cases affected from this infection. The reason was the change in 
climatic conditions and arrival of warm and wet weather. According to a survey, cattle 
(50%) and sheep (20%) livers were affected as a consequences of fluke infection 
(Abebe et al., 2010). 
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A simultaneous failure of three classes of differently acting anthelmintic agents 
(ivermectin, oxfendazole and morantel) was reported first time in New Zealand in 
1990, against nematodes that were derived from the goats, when these agents were 
administered to animals that belonged to different groups (Watson and Hosking, 
1990). 
 
 Mechanism of Drug Resistance 
 
Resistance against drugs can arise mostly in these possible ways. 
1.5.1.1 Mutation in the target site:  
 
Any change that occurs in the target molecules can affect the binding of drug to the 
target site because the drug moiety no longer recognises the target so no activity or 
effect of drug will initiate. For example, in case of some BZ, resistance arises because 
of mutations in β-tubulin isotype 1 and 2 (Demeler et al., 2013).  
In case of avermectins, it is the mutation of GluCl and/or GABA-R genes that are 
responsible for resistance. Levamisole resistant helminths showed changes in 
nicotinic acetylcholine receptors (Wolstenholme et al., 2004). 
1.5.1.2 Uptake of the drug:  
 
Any change in distribution of a drug to the target site can lead to resistance such as 
difficulty of a drug molecule to reach its target or removal of drug from the target due 
to p-glycoprotein efflux pumps (Figure 1.9). P-glycoproteins are membrane bound 
proteins that are members of ABC or ATP binding cassettes commonly known as 
transporter proteins. In 1976, Juliana and Ling, identified these transporters first time 
in cancer cells causing MDR (multi-drug resistance) against chemotherapeutic anti-
cancer agents. These proteins provide protection against external toxins found in food 
and environment (drugs) and in doing so they rescue cell and organelle from toxic 
effects of drugs. This resistance path presents a major problem in helminth’s diseases 
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therapy by producing resistant worms and one of the main cause in failure of 
anthelmintic drugs (Figure 1.9) (Broeks et al., 1995; Singh et al., 2015). 
For example, triclabendazole (TCBZ). Triclabendazole, a fasciolicide, is a very narrow 
spectrum BZ. Triclabendazole sulfoxide TCBZ.SO is an active form of TCBZ, it causes 
widespread shedding of tegument by blocking the tegumental secretions. In addition, 
it constrains mitotic cell division of spermatogenic cells which leads to microtubule 
disruption (Cancela et al., 2010). Studies showed TCBZ resistance was not associated 
with mutations in the ᵦ-tubulin molecule of the fluke. In TCBZ-resistant flukes, 
considerably lower level of TCBZ and TCBZ.SO were detected than in TCBZ-
susceptible flukes. This observation may suggest that P-glycoprotein-lined drug efflux 
pumps are associated with TCBZ resistance (Fairweather and Fairweather, 2005; 
Cancela et al., 2010). 
 
 
         
Figure 1. 9 Decreased uptake of drug by the cell due to mutation, so no drug at the target site, and 
uptake of drug molecule by p-gp receptors results in increased efflux or removal of the drug from the 
cell. 
 
1.5.1.3 A metabolic change  
A metabolic change that alters or prevents the drug activation or initiates its 
inactivation is also a cause of developing resistance (Zahreddine and Borden, 2013). 
H. contortus has a great tendency to develop resistance to anthelmintic agents 
because of this drug resistance become a major complication which threatens farm 
23 
 
produce and welfare of the animals (Matoušková et al., 2016; Raza et al., 2016). One 
of the Pharmacokinetic-mediated mechanism that involved in decreased drug efficacy 
or inactivation is metabolic change or altered metabolism. In this way, the 
concentration of the active drug at the target site (within parasite cells) is decreased, 
a lesser number of drug molecules bind to target receptors hence reducing drug effect. 
This type of resistance is the outcome of over-expression and increased activity of 
xenobiotic-metabolizing enzymes. These are the protein that provide string defense 
against potential harmful effects of drugs. Several studies described an evidence of 
direct link between drug resistance in nematodes and the xenobiotic-metabolizing 
enzymes (Brophy et al., 2012; Matoušková et al., 2016). 
It was evident in studies conducted on Haemonchous contortous that this nematode 
was able to metabolize albendazole (ABZ) and flubendazole (FLU) (Vokřál et al., 
2013).  
 
1.5.1.4 Target Gene amplification 
 
Drug resistance often leads to ‘survival of the fittest’ and reflect evolution, where a 
change in gene or gene expression is responsible for organism survival against a drug 
treatment. Gene amplification refers to increase in number of copies of a gene and 
this process is very common in cancer cells as well as in helminths. These amplified 
genes are responsible for helminth’s survival against drug treatment. Amplification can 
occur in the target genes or any other gene. Any change in gene expression can lead 
to an amplification of target gene by increasing its production that means not enough 
drug molecules available at the target site leading to a massive decrease in drug 
efficacy. In ivermectin-resistant H. contortus or T. circumcincta, an increase of low-
affinity L-glutamate-binding site was monitored that is a cause of resistance. Drug 
resistance against anti-parasitic drugs has been developed to a certain level where 
even Levamisol and BZ cannot be considered as highly effective anthelmintic drugs 




 Targeted Delivery by prodrug strategy 
 
The toxic efficacy and selectivity of anthelmintic can be improved by the use of prodrug 
forms that possess intracellular drug targeting moieties that may be able to circumvent 
P-gp type mediated resistance mechanism. The prodrug is a chemical entity (an 
inactive compound) that has no or less pharmacological activity against a specific 
target until after its metabolic transformation to an active or more active compound 
that has potential efficacy against that target.  (Hamada, 2017). 
Prodrug strategy is a practical way to improve availability of drug at the biological site. 
Prodrug approaches potentially can overcome all the barriers that decrease the drug’s 
benefits and its availability, these include; water solubility, drug stability, side effect 
profile, duration of an effect, safety index and taste of the drugs (Hamada, 2017; Ortiz 
de Montellano, 2013). Some conventional drugs are prodrugs because they can only 
be activated after a metabolic reaction or any modification. Examples include; 
Levodopa which is a precursor of dopamine, norepinephrine and epinephrine 
(neurotransmitters) (Levy et al., 2011). Numerous recent developments have occurred 
in designing prodrug strategies; these rely on possible modification for example 
amidation, benzylation, and esterification. One strategy in designing prodrugs involved 
the use of the drug or parent molecule with a hydroxyl group. One example of such a 
prodrug strategy is oseltamivir (an anti-inflammatory drug) which is an ester type 
prodrug (Cacciatore et al., 2018; Zawilska et al., 2013). 
The other strategy of prodrug design is to modify the hydroxyl (OH) group found in 
many drug molecules by carriers, targeting groups or self-eliminating linkers. These 
molecules possess changeable moieties such as sugars, amino acids, phosphate and 
organic acids. These moieties can be attached to the parent drug by a covalent bond 
and can be converted back to the parent molecule by specific enzymes such as sugar 
digesting enzymes, alkaline phosphatases, peptidases and esterases (El-Kamel et al., 
2008; Hamada, 2016). Prodrugs that contain hydrophilic moieties such as; sugars, 
amino acids and phosphates are water soluble in nature, their bioavailability is often 
higher as compared to the sparingly soluble and less efficient parent drug molecules. 
Recently a series of novel prodrugs of the sparingly soluble drug phenytoin has been 
designed and synthesised based on an arginine-methyl ester decomposition reaction. 
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The prodrug form can easily be converted into the parent molecule (Figure 1.10) in 
suitable physiological conditions. The research proved that phenytoin prodrug showed 
most promising effects and hence was more soluble as compared to parent drugs 
(Hamada, 2016). 
 















Figure 1. 10 Conversion of phenytoin prodrug (insoluble) into active parent drug (soluble) under 
physiological conditions. 
 
 Mitochondria, “a promising target” in chemotherapy  
 
Mitochondria are considered a power house of a cell. They are a small organelle within 
a cell that generate cellular energy in the form of ATP (adenosine triphosphate) 
(Milane et al., 2015). Apart from being a power generating house, mitochondria 
contribute to many functions of a cell that are important for survival and integrity of the 
cell (Zielonka et al., 2017a). Any defect or dysfunctionality of mitochondria can lead to 
several neurological and CVS (cardiovascular system) diseases. Mitochondria are 
vulnerable to oxidative stress (damage) that can contribute towards dysfunctioning of 
mitochondria and ultimately apoptosis (Picard et al., 2016; Vásquez-Trincado et al., 
2016). Some research in cancer therapy is focussed on selective targeting and 
accumulating MTAs (mitochondria targeting agents) in the matrix of mitochondria that 
in return interfere with proliferation process in cancer cells by generating ROS 




 Mitochondria targeting approaches 
 
A popular strategy over the past decade is to modify small drug molecule into a drug 
delivery vehicle to target mitochondria. This concept gained popularity because of 
effortless and easy synthesis process and maximum efficacy (Lu et al., 2016). 
There are two important mitochondrial targeting approaches: one includes conjugation 
of a therapeutic agent directly with a targeting moiety, for example, TPP conjugates 




 Introduction of Lipophilic cation: Triphenylphosphonium 
compound (TPP) 
 
TPP, triphenylphosphonium is a lipophilic, delocalised cationic carrier molecule that 
can be conjugated with different drug moieties by a specific linkage (such as an ester 
or amide linkage) that directs the drug to the target mitochondria site and potentially 
bypassing the resistance mechanisms and in doing so it will achieve maximum efficacy 
and decreased general toxicity to the host (Millard et al., 2010) (Figure 1.11). 





Figure 1. 11 Chemical structure of TPP (4-carboxybutyl) triphenylphosphonium). 
 
TPP and TPP-like cations were first used in the form of probes to better understand 
the mitochondrial membrane potential mechanism (Battogtokh et al., 2018). They are 
also utilised to deliver small drug molecules, antioxidants, vitamins and 
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pharmacophore to target mitochondria. Examples of lipophilic cations include 
triphenylphosphonium ions, peptides and rhodamine, these positively charged 
molecules can be attached to a drug molecule to ensure their mitochondrial uptake 
(Hardy et al., 2014). 
 
 Mitochondrial membrane potential 
 
Membrane potential ΔѰ is potential gradient that forces ions to move passively in one 
direction that means positively charged molecules are attracted towards the negative 
side of the membrane and vice versa. It represents an electrical potential difference 
between inside and outside of a physiological cell membrane. Mitochondrial 
membrane potential is one of the reasons behind selective uptake of lipophilic cations 
like TPP conjugated drugs by mitochondria. Drug moieties must cross both cell and 
mitochondrial membranes to reach the mitochondrial matrix. This step is easy for 
lipophilic cations such as TPP because the inner sides of the cell membrane and 
mitochondrial membrane are negative, that allows gradual accumulation of lipophilic 
cations first in the cytosol and then inside of the mitochondria. Membrane potential of 
plasma membrane is 30-60 mv (negative inside, positive outside) that causes 3-5 
times increase in the penetration of cations in the cytosol as compared to extracellular 
environment. In addition, membrane potential of mitochondrial membrane is 
approximately 150-180 mV and that favours easy passage of lipophilic cations to the 
matrix of mitochondria (Román Luque-Ortega et al., 2010; Zielonka et al., 2017a). 
It was stated that due to membrane potential of mitochondrial inner membrane 
(negative inside) drug molecules with the positive charged carriers penetrate through 
the mitochondrial membrane and gathers in the matrix. Targeting mitochondria using 
TPP molecule in the form of prodrug is not a new approach as plentiful literature 




 Hydrophobicity of TPP Drug complex 
 
Membrane potential and charge on the molecule is not the only reason for attracting 
cationic compounds inside the mitochondria, but there is another significant feature 
that facilitates passage of lipophilic cations through the lipid bilayer membrane and 
that is hydrophobicity or lipophilicity of the compounds. High lipophilicity of a 
compound means increase uptake by mitochondria and vice versa (Ross et al., 2005). 
TPP was employed to functionalised conventional nanoparticles such as liposomes 
and dendritic polymers targeting mitochondria. These polymers showed great deal of 
specificity in targeting mitochondria in the presence of TPP, because of this they may 
be considered as second-generation drug delivery systems (DDS’s). In vitro 
experiments proved that these TPP conjugated polymers showed promising results by 
not only successfully enter the cell membrane and accumulated inside the 
mitochondria, but also remained stable and intact during this process until they reach 
to the target site that is mitochondria (Paleos et al., 2016). 
A series of novel compounds have been synthesised that composed of mitochondrial 
targeting antioxidants in which TPP was linked to the antioxidant vitamin E by an alkyl 
linker. All the synthesised compounds were mitochondrial targeting vitamin E 
derivatives (mito-E analogues) and possessed varying degree of hydrophobicity 
depending on different linkers of different lengths. These analogues presented 
maximum degree of efficiency by accumulating in the matrix of mitochondria (Jameson 
et al., 2015). 
 
 TPP application as a “magic bullet” in targeted drug delivery 
 
TPP conjugated drug applications were initiated by Murphy and co-researchers 
(Coulter et al., 2000; Murphy, 1997). TPP based drug conjugates have significant 
advantages over other targeted delivery vehicles that include: straightforward 
synthesis and purification, stability of TPP molecule in a living system, mixture of 
lipophilic and hydrophilic properties in a same conjugate and non-reactivity towards 
other components of cell (Zielonka et al., 2017). A variety of researches have been 
conducted based on the direct conjugation of triphenylphosphonium cations with anti-
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cancer drugs or antioxidants since 1995 when Murphy’s group conducted a study 
based on mitochondria targeting conjugates with antioxidants (Burns et al., 1995). It 
is now proved by studies that anticancer drugs or any antioxidant when conjugated 
directly with a MTA (mitochondrial targeting agent) is capable of increasing cytotoxicity 
and anti-oxidising property by localizing specifically to mitochondria in comparison with 
their parent drugs that has no targeting moiety attached (Battogtokh et al., 2018). In a 
recent study TPP was linked to anti-cancer agents; betulin and betulinic acid to 
achieve specificity in targeting mitochondria of cancer cells. These agents were of 
limited use before due to some limitations such as poor bioavailability, poor water 
solubility and low intracellular acquisition. These problems were solved by the 
application of TPP-drug complex (Figure 1.12).  










Figure 1. 12 TPP-betulin prodrug complex (showing ester bond) and its non-prodrug form betulin. 
Results from different assays showed that these targeted agents with attached TPP 
exhibited increased uptake, significant cytotoxicity and selectivity between cancer 
cells and normal cells as compared to non-conjugated parent drugs betulin and 
betulinic acid (Ye et al., 2017). 
Strobykina et al., (2015), synthesised a series of novel anti-mitotic agents in which 
TPP moiety was used as a delivery vehicle to achieve selectivity in terms of 
accumulating in the matrix of mitochondria. The compounds comprised of diterpenoid 
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isosteviol attached with TPP cations. In an assay, isosteviol-TPP complex when tested 
on fertilised eggs, induced mitotic arrest by acting on mitochondrial DNA. TPP based 
targeting approach is considered as most promising when it comes to the selective 
targeting and cytotoxic efficiency in cancer therapy without producing off-target effects.                                                                                                           
Millard et al., (2013), designed and synthesised a novel TPP derivative of nitrogen 
mustard chlorambucil called, Mito-chlor. Nitrogen mustard excessively used 
chemotherapeutic agent but was limited in efficacy and safety profile. By synthesising 
it as a TPP conjugate, it has overcome these limitations. Mito-chlor was able to localise 
on cancer cell mitochondria and produce apoptosis by arresting cell cycles in breast 
and pancreatic cancer cells as compared to parent drug molecule that was unable to 
show any toxicity. 
 Caenorhabditis elegans as a Model Organism        
                                                        
In 1963, Sydney Brenner proposed that the success of molecular biology is because 
of presence of extremely simple model system, such as a simple organism that can 
be controlled and handled even if it is in large numbers (Brenner, 1974). Brenner 
introduced C. elegans as a model system for conducting research in developmental 
biology (Kaletta and Hengartner, 2006a). After his introduction, this organism has been 
widely used as a research tool (Kenyon, 1988). 
 
 Properties of C. elegans as a model experimental system 
 
Caenorhabditis elegans or C. elegans is a free living, non-parasitic roundworm or 
nematode naturally exist in soil of temperate climate (Culetto, 2000; Labouesse, 2003) 
. C.elegans is an excellent model organism and favoured by the scientist because of 
its amazing properties such as, its small size (1 mm) that makes it easily maintained, 
transparency (transparent from outside that makes it easy to observe and manipulate) 
and it is very easy to work with in the laboratories. It can be easily cultivated and 
housed in large numbers such as 10,000 worms/petri dish (Buckingham et al., 2014; 
Kaletta and Hengartner, 2006b; Kenyon, 1988). C.elegans can also be maintained in 
liquid culture. It can swim using an oscillating, stereotyped body motion that can be 
either indirect assay to monitor organism health or a direct representation of the 
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neuromuscular system. The swimming rate or thrashing (number of folds or bend per 
minute) can be measured manually (Buckingham et al., 2014). 
The life cycle of C. elegans is very short, it takes about 3 days from egg to egg, life 
span is about 2-3 weeks and this short life cycle facilitates biological research because 




Figure 1. 13 Life cycle of C. elegans at 25 ºC (Donald L Riddle, 1997). 
 
 
Due to unfavourable conditions, that can be either change in environment or food 
deprivation, in the life cycle of C. elegans the L1 or L2 Larvae stage can convert into 
the Dauer stage, which is the most stable stage (Figure 1.13) (Cassada and Russell, 



















C.elegans has 6 pairs of chromosomes in which 5 pairs are autosomes and one pair 
of sex chromosomes. It has 2 sex types; males and hermaphrodites. The type of the 
sex depends on the 6th pair of sex chromosome, if it is XX it will be a hermaphrodite 
and if it is XO it will be a male. Hermaphrodites are the most common sex in nature 
and are capable of self-fertilisation. It can produce 300-350 offspring’s in self-
fertilisation. Self-fertilisation of hermaphrodite can be manipulated in the laboratories 
to generate progeny with specific genotype that can especially helpful in genetic 
research (Woods et al., 2011). 
 
 Non-Animal Model & 3R’s 
 
C.elegans also complies with the “3 R’s Principles” for animal experiments that are 
widely accepted ethical principles, which demonstrate as: 1) Reduction of the higher 
animal use, 2) Refinement of current techniques and 3) finally replacement of animals 
with alternative systems (De Boer et al., 2015). 
 
 Comparison of C. elegans with other vertebrate models 
 
Other vertebrate models such as zebrafish (Danio rerio) and mice are the most 
experimented models in laboratory because of their homology with human beings but 
their exploitation is much more complex, and they have longer life cycles (Hulme, 
2011). 
 
 Homology with humans 
 
In 1998, C. elegans was the first multicellular organism whose genome was fully 
sequenced. Its genome is approximately hundred million base pairs long, no doubt 
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that it is smaller than human genome but possess same number of genes (C. elegans 
20,000 genes; humans 23,000). According to bioinformatics analysis 60-80% of 
homology exist between worm and human and that makes its application favourable 
to study human genetic disorders (Berezikov, 2004; Driscoll et al., 1989). 
This altogether makes its use as a model of parasitic nematodes in anthelmintic drug 






















Chapter   2 
2  Results & Discussion  
 
Resistance is the hallmark when it comes to the efficacy of anthelmintic agents and a 
major cause of their failure (Howard J. Atkinson et al., 2012; Ray M Kaplan, 2004; 
Scott et al., 2013). Selectivity and toxic efficacy can be improved by a prodrug design 
strategy by incorporation of a targeted moiety in the main drug design that target the 
anthelmintic agents to the target site i.e. helminths. This chapter presents the results 
and discussion of the design, synthesis and biological evaluation of novel potential 
anthelmintic prodrugs based on colchicine-derived compounds that were substituted 
with different amino alcohols (or diamines) to establish any structure-activity 
relationships within the closely structurally related series. In order to achieve selectivity 
and toxic efficacy, these novel agents are further conjugated with TPP, 
triphenylphosphonium cations, as a ‘smart’ carrier to produce highly efficient prodrugs 
that might function as Magic Bullets (Finichiu et al., 2013).  
TPP or triphenylphosphonium ions are one of the most studied and successfully used 
lipophilic cations can be easily accumulated into the matrix of mitochondria due to its 
highly delocalised positive charge and highly lipophilic or hydrophobic nature that 
would encourage easy passing from the lipid bilayer of not only a cell membrane but 
also from the mitochondrial membrane; in doing so, it could not only prevent the host 
from general toxicity by selective targeting to helminth’s mitochondria but also has the 
potential to circumvent the acquired drug resistance (Finichiu et al., 2013; Zielonka et 
al., 2017). 
 
 Design strategy for novel amino-colchicines 
 
In this project, these novel potential anthelmintic prodrugs are amino colchicine 
derivatives, further conjugated with TPP for the targeted drug delivery. The general 
design includes production (synthesis) of novel amino colchicine derivatives with 
aminoalcohols and diamines to provide the substrate for ester (in case of amino 
alcohol) and amide (in case of diamine) bond formation to afford the target 
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compounds. Colchicine was derivatised at carbon-10 with amino-alcohols to generate 
these novel amino-colchicine derivatives. The series (code-named AM) includes AM1 
(colchicine-prolinol), AM3 (colchicine-4-hydroxypiperidine) and AM4 (colchicine-(R)-3-
pyrolidinol) (Figures 2.1 & 2.2). 
 
Figure 2. 1 General design strategy of amino-colchicine derivatives with amino-alcohol. Where R1 can 



























                                           













Figure 2. 2 Structures of selected colchicine derivatives with amino-alcohols AM1 (colchicine-prolinol) 




Another design strategy was used in which colchicine was derivatised with a diamine 
to produce AM5 (Colchicine-(R)-3-(Boc-aminopyrrolidine) and AM6 (Col-(R)-3-
aminopyrrolidine-TFA) (Figures 2.3 & 2.4).  
 
Figure 2. 3 General design strategy of amino-colchicine derivatives with diamine. Where R1 is H or part 
of carbocyclic ring R is part of carbocyclic ring, exemplified by 3-aminopyrrolidine in which R2 is Boc at 

















































 Prodrug design strategy for novel amino-colchicines in 
conjugation with TPP  
 
These aminocolchicine derivatives were further conjugated with TPP in order to 
synthesise novel targeted prodrugs. The series includes AM2 (Colchicine-prolinol-
TPP), AM7 Col-(R)-3-aminopyrrolidine-TPP). (Figure 2.6), AM8 (Colchicine-4-
hydroxypiperidine-TPP) and AM9 (Colchicine-(R)-3-Pyrrolidinol-TPP). Figure 2.5 
shows the structures of these colchicine derivatives and their TPP linked conjugates.        




Figure 2. 5 TPP-linked colchicine derivatives; AM2 (Colchicine-Prolinol-TPP), AM8 (Colchicine-4-






           
Figure 2. 6 TPP-linked colchicine derivative with diamine AM7 Col-(R)-3-aminopyrrolidine-TPP. 
 
 Overview of the project 
 
The earlier parts are an outline of design strategy of AM series and the following 
section describe in detail the rational design, synthetic strategy (solution-based 
synthesis methods), purification processes, chemical characterisation (mass 
spectrometry, NMR spectroscopy) and biological evaluation. Biological evaluation 
includes C. elegans viability assay. The C. elegans worm was used as model organism 
for evaluating potential anthelmintic properties of these prodrugs, partition coefficient 
assay to determine the lipophilicity of these agents and molecular docking studies on 






 Rationale design of TPP-linked amino-colchicine Prodrugs 
 
This section describes the design of novel colchicine derivatives and their TPP-linked 
prodrugs. The TPP-linked prodrugs utilised a three components structure design that 
included a colchicine substituent with an amino alcohol (different in each drug, to act 
as a linker between colchicine & TPP, and to provide an ester substrate for the action 
of esterase) and with a diamine (to provide a substrate for amidase or peptidase in the 
system) and TPP, as a carrier for targeted mitochondrial drug delivery.  
Colchicine, that is a known small molecule drug, currently being used as an anti-
inflammatory agent in the treatment of gout or Mediterranean fever, is an alkaloidal 
drug obtained from the floral extract of Colchicum autumnale. Studies demonstrated 
that colchicine interferes with the microtubule assembly by binding with the protein 
tubulin that consequently leads to disruption of various functions associated with 
microtubules including cellular chemotaxis, mitosis and phagocytosis (Dalbeth et al., 
2014). Colchicine has a high binding affinity for tubulin (a basic unit of microtubules). 
It binds at the interface of α and β sub-units and forms a curved tubulin dimer due to 
steric interaction of colchicine and the tubulin The derived curved dimer then further 
stops the polymerisation, depolymerises microtubules and inhibits the assembly of 
microtubules (Ravelli et al., 2004). 
There are three main rings of the colchicine structure, a six-membered benzene ring 
A, a heptane ring B, and another heptane ring C (the tropolone ring) (Figure 2.7). It 
has been known by SAR of colchicine from the literature, that A and C rings of 
colchicine are important structural features in relation to its high binding affinity for 
tubulin and intrinsic biological activity. Any changes in the A-ring can lead to loss of 
binding affinity to tubulin but modification can be made on ring B and at the C-7 and 
C-10 positions in the colchicine (Dong et al., 2016; Fournier-Dit-Chabert et al., 2012; 
Zhang et al., 2015). In this study, modification was made to the C-ring of colchicine at 
the C-10 position by addition of amino-alcohols in the case of AM1, AM3, and AM4 























Figure 2. 7 Colchicine with all the rings and showing position C-10 for modification. 
 
Although colchicine has no direct action on mitochondria, depolymerisation of 
microtubules affects mitochondrial biogenesis, this is because MT are a part of 
cytoskeletal and play a main role in spindle dynamics during anaphase of mitosis and 
inhibit formation of mitochondrial content (Karbowski et al., 2006). Colchicine is not 
known as anthelmintic drug but it shares an important feature with a well-known class 
of anthelmintics, the benzimidazoles, that is they both bind at the same colchicine 
binding site on the tubulin molecule (Lu et al., 2012). In part, motivation comes from 
the known antitubulin action of the benzimidazole class of anthelmintics and the need 
to develop more potent alternatives that bypass resistance. In preliminary work, 
hydroxyethylaminodeoxycolchicine has been shown to have significant toxic potency 
in the nonparasitic C. elegans model organism.  
This was the main motivation behind developing the potential anthelmintic pro-drugs 
described in the current research. Research also revealed that selection of 
benzimidazoles over other anthelmintic is also encouraged due to the ability of host 
cells to undergo genetic transformation that would block the MT (microtubules) 
disruption caused by benzimidazoles or by drugs similar to benzimidazoles, as 
compared to worm cell (Aleyasin et al., 2015). 
Toxicity is the major challenge when it comes to the therapeutic efficacy of colchicine 
derivatives because of its low therapeutic index. This challenge can be addressed by 
designing its prodrug forms by an addition of targeted carrier molecule such as TPP 
and targeting drugs to the site of action (which is in this case the worm’s mitochondria) 
that would not only reduce general toxicity to host but also circumvent the possible 
resistance mechanisms against typical anthelmintic drugs. An approach that would 
exploit the negative membrane potential of inner membrane of mitochondria and would 
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attract lipophilic cations, like TPP and draw them towards the matrix of mitochondria, 
is needed. TPP is one of the less toxic lipophilic carrier cations among other cations 
used for the same purpose such as rhodamine-123 and thiopyrylium AA1, to deliver 
drugs or to detect the localisation of drug molecule at the target site (Modica-
Napolitano et al., 1984). An early report (Levi-Schaffer et al., 1984) showed that 
lipophilic, cationic phosphonium compounds had some significant toxicity towards 
adult Schistosoma mansoni worms and had been shown to act as inhibitors of 
acetylcholinesterase (AChE). In a study, phosphonium lipo-cationic derivatives of 
betulin and betulinic acid have shown potential as antiparasitic agents against S. 
mansoni (Spivak et al., 2014). 
Mitochondria which are a main target in this study, are the power generating 
organelles in a cell, apart from this main function they also produce ROS (reactive 
oxygen species). Production of ROS is a sign of oxidative stress and involves in the 
destruction of other biomolecules in a cell. Hence oxidative stress which is responsible 
for aging and cell death can originate from dysfunction of mitochondria (Balaban et al., 
2005). Payne and Chinnery, 2015 suggested that mutated mitochondrial DNA may 
produce metabolic abnormalities in mitochondria and is a main reason that implicate 
aging is mediated through apoptosis. Hence, considering the main role of mitochondria 
in cell death and cellular functions, the recent research selects mitochondria as a main 
target for TPP-linked colchicine derivatives in the therapy of helminth diseases. 
Studies demonstrate that TPP conjugates are safer and less toxic to the mammalian 
cell as compared to parasitic helminth cell. This is because helminth’s cell membrane 
is even more negative as compared to the host cell, this feature also encourages TPP-
linked prodrugs to be more attracted towards the helminth cell and not to the host 
mammalian cell. This was proved by different studies where drug complexes were 
found to be accumulated in the helminth cell as compared to a host cell (Román 
Luque-Ortega et al., 2010). 
The novel anthelmintic amino-colchicine derivatives were designed in a prodrug form 
by conjugating with TPP (for targeted delivery of these agents) that will release active 
drugs as amino-colchicine in the mitochondrial matrix. TPP was attached with amino 
alcohol or a diamine with the formation of an ester bond (or in AM7 an amide bond) 
that would cleave in a biological system by an enzyme an esterase or amidase (for 
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AM7) to liberate the active drug amino-colchicine derivatives and TPP at the site of 
action (worm’s mitochondria). Figure 2.8 shows the prodrug activation concept.  
 
 
Figure 2. 8 A Prodrug activation concept of TPP-linked colchicine derivatives (the AM series), as 
potential anthelmintic agents, showing cleavage by an esterase between TPP and the amino-alcohol.  
 
The objective behind the current study was to investigate the potential of novel 
colchicine based prodrugs as anthelmintic agents and in the longer term, to 
demonstrate the mechanism of action of the colchicine derivatives in depolymerisation 
of MT that would in turn disrupt the mitochondrion function and have the potential to 




 Synthesis Strategy: 
 



























Reagents and conditions: (i) Prolinol {(S)-pyrrolidin-2-yl methanol}, DMF, 20 °C, 24 h. 
Figure 2. 9 Synthesis of Col-prolinol (AM1) from Colchicine. 
 
AM1 was synthesised by dissolving colchicine and prolinol in DMF, then the reaction 
mixture was stirred and kept for 24 h at room temperature (Figure 2.9). Solvent 
extraction was performed to remove excess amount of DMF with chloroform/water 
mixture and the progress of the reaction was monitored by TLC which showed 
completion of the reaction with the formation a new yellow spot in the product lane 
running higher than the starting material. Crude product (AM1) was purified by silica 
gel column chromatography, firstly, chloroform was used as a mobile phase to remove 
the high running impurities in the mixture and unreacted colchicine, then chloroform: 
methanol (9:1) and (4:1) and lastly methanol alone was used (in order of increasing 
polarity) to elute AM1. All the fractions containing pure AM1 (confirmed by TLC) were 
eluted, combined and filtered to remove silica, evaporated to reduce the volume, 
cooled over ice bath and finally diethyl ether was added into the mixture to get a yellow 
precipitate of Col-prolinol (AM1). The precipitate was filtered and dried to afford yellow 
solid AM1 in a good yield. 
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AM1 was characterised by its MS (ESI+) mass spectrum that showed a signal at m/z 
469.23 Da (M+H)+  for the species [C26H32N2O6]+  and its sodium adduct at m/z 491.21 
(M+Na)+ and confirmed the molecular mass of 468.23 Da. (Figures 2.10 and 2.11)                                                                                              
           
Figure 2. 10 ESI (+) Mass spectrum of AM1 (Col-prolinol).  
          




The structure of the compound was also confirmed by its 1H NMR spectrum. A three-
proton multiplet at 1.69-1.90 ppm was assigned to a methylene group of N-CH2-CH2 
and one of the CH protons of C6. The three-proton singlet was assigned to the methyl 
group of the acetamide substituent at 2.03 ppm. The three-proton multiplet at 2.38 
ppm was assigned to the methylene CH2 group of C5 and the CH proton of C6. 












































Figure 2. 12  1H NMR assignments (ppm values) and atomic numbering.  
  
A two-proton multiplet at 3.40-3.50 ppm was assigned to the methylene CH2 of the 
prolinol ring (N-CH2-CH2-CH2). A three-proton singlet at 3.64 ppm was assigned to the 
methoxy group of C1 (C1-OCH3). Methylene protons (next to nitrogen, N-CH2) were 
assigned to a two-proton multiplet at 3.70 ppm. A methoxy group protons at C3 were 
assigned to a three-proton singlet at 3.90 ppm. A three-proton, singlet at 3.95 ppm 
was assigned to the methoxy group of C2. A one-proton multiplet at 4.57 ppm was 
assigned to the methane of C7 (H-7). A one-proton doublet at 6.49 ppm, with J=12 Hz 
was assigned to the aromatic H-11 proton. A methine proton of C4 was assigned to a 
one-proton singlet found at 6.54 ppm. A methine proton of C8 was assigned to a one-
proton multiplet found at 7.24 ppm. A one-proton, doublet with J= 12 Hz, at 7.30 ppm 
was assigned to the aromatic methine proton of C12 (H-12). A doublet was assigned 
to a proton attached to nitrogen of acetamide found at 7.66 ppm that is coupled to H7 
(Figure 2.12). 
Additionally, the 13C NMR spectrum showed signals from all the carbon atoms.  
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Figure 2. 13  13C NMR signals with assignments (ppm values) and atomic numbering 
A DEPT experiment differentiated the methyl, methylene and methine carbons from 
the remaining quaternary carbon group signals. A negative signal at 22.46 ppm was 
assigned to a methylene carbon CH2. A positive signal at 22.93 ppm was assigned to 
the methoxy C14 carbon. A negative signal at 28.07 ppm was assigned to a further 
methylene CH2 carbon. A methylene CH2 negative signal was assigned to C5 carbon 
at 30.07 ppm. A negative signal at 37.35 ppm was assigned to a methylene of C6. A 
negative signal of a methylene carbon was found at 50.63 ppm.  A positive signal of a 
methine carbon, C7 was found at 52.09 ppm. Three positive signals of the three methyl 
carbons C3, C2 and C1 were found at 56.10 ppm, 61.28 ppm and 61.42 ppm 
respectively. A positive signal of the alpha carbon of prolinol was found at 62.23 ppm. 
A negative signal of a methylene (CH2) of carbon adjacent to the OH group was found 
at 64.15 ppm. A positive signal of a methine carbon assigned to C4 was found at 
107.41 ppm. A positive signal of the methine carbon of C11 was found at 113.25 ppm. 
A methine carbon of C8 was found at 123.66 ppm. A positive signal was assigned to 
methine CH carbon of C12 found at 138.31 ppm. The remaining quaternary carbon 
signals of colchicine (ring A, B and C) were found at 126.22, 129.85, 134.72, 141.52, 
150.18, 151.33, 152.95, 156.23 and 176.73 ppm. A quaternary carbon of carbonyl 



































Reagents and conditions: (i) Col-Pro (AM1), TPP, DCC, DMAP, CH2Cl2 (dichloromethane), rt, 24 h. 
Figure 2. 14 Synthesis of Col-prolinol-TPP (AM2) from Col-Pro (AM1). 
To synthesise AM2 (Col-Prolinol-TPP), AM1 (Col-Prolinol-OH) was conjugated with 
TPP by an esterification reaction between the carboxylic acid group (COOH) of TPP 
and hydroxyl (OH) group of prolinol in AM1, where the carboxylic group of TPP was 
activated by DCC as a coupling agent and DMAP (as a basic catalyst) and enhancer. 
These bases induce coupling between an alcohol or amide and a carboxyl group and 
initiate formation of an active ester or an amide bond (Figure 2.14). Activated TPP 
was added to AM1 dissolved in dichloromethane (CH2Cl2). The progress of the 
reaction was monitored by TLC. Once the reaction was completed solvent extraction 
(Chloroform/water) was performed to remove extra TPP or unreacted TPP and to 
convert DCC into DCU that then was removed by filtration. TLC was performed that 
showed successful formation of the new AM2 product as a yellow spot running lower 
than AM1 (starting material) in the product lane. The crude compound AM2 was 
purified by silica gel chromatography (chloroform: methanol, 9:1 and 4:1) with order of 
increased polarity. All the fractions containing AM1 (confirmed by TLC) were eluted 
but some solid crystals of DCU and water was present in all the fraction. So, anhydrous 
sodium sulfate drying agent was added to the combined fractions. The filtered fractions 
were evaporated, cooled over ice bath and finally diethyl ether was added to get 
precipitates of pure AM2 compound. AM2 was characterised by its MS (ESI+) mass 
spectrum that showed a signal at m/z 813.36 Da (M+H)+  for the cationic species 




   
Figure 2. 15 ESI (+) Mass spectrum of AM1 (Col-prolinol)  
 
      

































Figure 2. 17  1H NMR signals and assignments (ppm values) and atomic numbering.  
A five proton multiplet at 1.50-1.80 ppm was assigned to two methylene CH2 groups 
of OCOCH2-CH2-CH2-CH2-P and one of the methine CH of C6. The three-proton 
singlet was assigned to the methyl group of acetamide at 1.85 ppm. The five-proton 
multiplet at 1.90-1.96 ppm was assigned to the methylene CH2 of C5, and of prolinol 
NCH2-CH2 and methine CH of C6. A three-proton triplet at 2.17-2.36 ppm was 
assigned to a methylene of CH2-CO. A three protons singlet at 3.47 ppm was assigned 
to the methoxy group of C1 (C1-OCH3). A four-proton multiplet at 3.54 - 3.66 ppm was 
assigned to the one of the methylene CH2 of prolinol (N-CH2-CH2-CH2) and to a 
methylene adjacent to N (N-CH2). A methoxy proton at C3 was assigned to a three-
proton singlet at 3.77 ppm. A three-proton, singlet at 3.83 ppm was assigned to the 
methoxy group of C2. One-proton multiplet at 4.34 ppm was assigned to the methine 
of C7 (H-7). A one-hydrogen multiplet at 4.99 ppm was assigned to methine CH 
adjacent to CH-CH2-OCO. One-proton doublet at 6.50-6.52 ppm, with J=12 Hz was 
assigned to the aromatic of H-11 (C11) proton. A methine proton of C4 was assigned 
to one-proton singlet found at 6.72 ppm. A methine proton of C8 was assigned to one-
proton multiplet found at 6.84 ppm. A one-proton, doublet with J = 12 Hz, centred at 
6.95-6.99 ppm was assigned to the aromatic methine of C12 (or H-12). A fifteen-proton 
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multiplet was assigned to TPP at 7.76-7.93 ppm. A doublet was assigned to a proton, 
attached to nitrogen of acetamide NH (acetamide nitrogen) (Figure 2.17). 
 Synthesis of Colchicine-4-hydroxypiperidine (AM3) 
 
AM3 (Colchicine-4-hydroxypiperidine) was synthesised by reacting colchicine with an 
excess of 4-hydroxypiperidine in DMF, then the reaction mixture was stirred and kept 























Reagents and conditions: (i) 4-hydroxypiperidine, DMF, rt, 48 h. 
Figure 2. 18  Synthesis of Colchicine-4-hydroxypiperidine (AM3) from Colchicine. 
 
Solvent extraction was performed to remove excess amount of unreacted amino 
alcohol used in the reaction (because it was found that 4-hydroxypiperidine was 
soluble in the water) and DMF with chloroform/water mixture. White solid particles 
were found in the reaction therefore filtration was performed before extraction to 
remove those white solid particles. The progress of the reaction was monitored by TLC 
which showed completion of the reaction with a new yellow spot in the product lane 
running lower than the starting material (colchicine as reference).  
Crude product (AM3) was purified by silica gel column chromatography, firstly, 
chloroform was used as a mobile phase to remove the front running impurities in the 
mixture and unreacted colchicine, then chloroform: methanol (9:1) and (4:1) was used 
to elute AM3. All the fractions containing pure AM1 (confirmed by TLC) were eluted, 
combined and filtered to remove silica, evaporated to reduce the volume, cooled over 
ice bath and finally diethyl ether was added into the mixture to get a yellow precipitate 
of Col-4-hydroxypiperidine (AM3). The precipitate was filtered and dried to get yellow 
solid AM3 in a good yield. AM3 was characterised by MS (ESI) mass spectrum that 
showed a signal at m/z 469.23 Da in (M+H)+  for the cationic species [C26H32N2O6]+ 
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and its sodium adduct 491.21 (M+Na)+ and confirmed the molecular mass of 468.23 
Da. (Figures 2.19 and 2.20)     
 
Figure 2. 19 ESI (+) Mass spectrum of AM3 (Col--4-hydroxypiperidine). 
 
Figure 2. 20 Comparison of the observed data with the theoretical isotope model of AM3. 
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The structure of the compound was also confirmed by its 1H NMR spectrum. 










































Figure 2. 21 1H NMR signals and assignments (ppm values) and atomic numbering.  
 
A three-proton multiplet at 1.74-1.83 ppm was assigned to a methylene of N-CH2-CH2 
and one of the CH of C6. A five-proton singlet was assigned to the methyl group of 
acetamide and methylene of N-CH2-CH2 at 2.03 ppm. The three-proton multiplet at 
2.17 ppm was assigned to methine (CH) of C6 and methylene (CH2) of N-CH2-CH2 
(the other side of the hydroxypiperidine). A two-proton multiplet at 2.45 ppm was 
assigned to the methylene CH2 of C5. A one-proton multiplet at 3.26 ppm was 
assigned to OH of hydroxypiperidine (CH-OH). A three protons singlet at 3.67 ppm 
was assigned to the methoxy group of C1 (C1-OCH3). Eight proton singlets were found 
at 3.85-4.05 ppm was assigned to two methoxy groups (OCH3) of C3 and C2 and a 
methylene of N-CH2. A proton multiplet at 4.61-4.69 ppm was assigned to methine of 
C7 (H7) adjacent to acetamide CH-NHCOCH3. A methine proton of C4 was assigned 
to one-proton singlet found at 6.53 ppm. One-proton doublet at 6.83 ppm, with J=12 
was assigned to the aromatic of H-11 (C11) proton. A one-proton, doublet with J= 12, 
at 7.23 ppm was assigned to the aromatic methine of C12 (or H-12). A methine proton 
of C8 was assigned to one-proton singlet found at 7.25 ppm. A doublet was assigned 
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to a proton attached to nitrogen of acetamide (NH-COCH3) found at 7.53 ppm that is 
adjacent to C7 (Figure 2.21). 
Additionally, 13C NMR spectrum showed signals from all the carbon atoms.  




















































Figure 2. 22 13C NMR with assignments (ppm values) and atomic numbering 
 
A DEPT experiment differentiated the methyl, methylene and methine carbons from 
the remaining quaternary carbon group signals. A positive signal at 22.98 ppm was 
assigned to the methoxy C14 carbon. A methylene CH2 and a negative signal was 
assigned to C5 carbon at 30.09 ppm. A negative signal at 34.30 ppm and 34.39 ppm 
was assigned to methylene CH2 carbon of C3’ and C5’. A negative signal at 36.96 ppm 
was assigned to a methylene of C6 carbon. Two negative signals at 46.32 ppm and 
46.45 ppm were assigned to methylene CH2 of C2’ and C6’. A positive signal of a 
methine carbon, C7 was found at 51.91 ppm. Three positive signals of the three methyl 
carbons C3, C2 and C1 were found at 56.12 ppm, 61.40 ppm and 61.44 ppm 
respectively. A positive signal of alpha carbon C4’ of hydroxypiperidine was found at 
67.41 ppm. A positive signal of a methine carbon assigned to C4 was found at 107.34 
ppm. A positive signal of the methine carbon of C11 was found at 118.17 ppm. A 
methine carbon of C8 was found at 128.82 ppm. A positive signal was assigned to 
methine CH carbon of C12 found at 136.25 ppm. The remaining quaternary carbon 
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signals of colchicine (ring A, B and C) were found at 126.08, 133.84, 134.40, 141.60, 
149.72, 151.29, 153.11 and 158.38 ppm. A quaternary carbon of carbonyl group of C9 
and C13 (acetamide) was found at 181.32 and 169.89 ppm respectively (Figure 2.22).  
 


























Reagents and conditions: (i) (R)-3-Pyrrolidinol, DMF, rt, 1 h.  
Figure 2. 23 Synthesis of Colchicine-(R)-3-Pyrrolidinol (AM4) from colchicine. 
AM4 (Colchicine-(R)-3-Pyrrolidinol) was synthesised by reacting colchicine and (R)-3-
pyrrolidinol in DMF, then the reaction mixture was stirred and kept for 1 hour at room 
temperature (Figure 2.23). The progress of the reaction was monitored by TLC which 
showed completion of the reaction with a new yellow spot in the product lane running 
lower than the starting material (colchicine) reference. 
Crude product (AM4) was purified by silica gel column chromatography, firstly, 
dichloromethane was used as a mobile phase to remove the high running impurities 
in the mixture and unreacted colchicine, then dichloromethane: ethanol (9.5: 0.5) and 
dichloromethane: methanol (9:1) was used to elute out the pure AM4 compound. All 
the fractions containing pure AM4 (confirmed by TLC) were eluted, combined and 
filtered to remove silica and evaporated to reduce the volume. It was noticed that 
brownish sticky material was present after vacuum evaporation in the RBF. It was 
anticipated that it could be the unreacted amino alcohol (R)-3-pyrrolidinol) or DMF. 
The excess amount of DMF and amino alcohol was removed by solvent extraction 
(chloroform/water). AM4 solution in chloroform was evaporated to reduce its volume, 
cooled over an ice bath and finally diethyl ether was added into the mixture to get a 
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yellow precipitate of Col-(R)-3-pyrrolidinol (AM4). The precipitate was filtered and dried 
to get yellow solid AM4 in a good yield. 
AM4 was characterised by MS (ESI+) mass spectrum that showed a signal at m/z 
455.22 Da (M+H)+ for the cationic species [C25H31N2O6]+  and its sodium adduct 477.20 
(M+Na)+ and confirmed the molecular mass of 454.22 Da. (Figures 2.24 and 2.25)  
 
 




Figure 2. 25 Comparison of the observed data with the theoretical isotope model of AM4. 
 
The structure of the compound was also confirmed by its 1H NMR spectrum. 
















































Figure 2. 26 1H NMR assignments (ppm values) and atomic numbering.  
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A proton multiplet was assigned to one of CH of C6 at 1.80 ppm. A three-proton singlet 
was assigned to the methyl group of acetamide at 2.03 ppm. A three-proton multiplet 
at 2.07-2.30 ppm was assigned to a methylene of N-CH2-CH2 and one of the CH of 
C6. A two-proton multiplet at 2.43 ppm was assigned to the methylene CH2 of C5. A 
three protons singlet at 3.67 ppm was assigned to the methoxy group of C1 (C1-
OCH3). A four-proton multiplet was assigned to two of the methylene (CH2) adjacent 
to N (2xN-CH2) at 3.78-3.87 ppm. A three-proton singlet at 3.90 ppm was assigned to 
the methyl of C3. A three-proton singlet of the methyl of C2 were found at 3.95 ppm.  
A proton doublet was assigned to OH adjacent to CH found at 4.07 ppm. A proton 
multiplet at 4.55 ppm was assigned to the methine CH attached to OH. A proton 
multiplet at 4.60 ppm was assigned to methine of C7 (H7) adjacent to acetamide CH-
NHCOCH3. One-proton doublet at 6.41 ppm was assigned to the aromatic of H-11 
(C11) proton. A methine proton of C4 was assigned to one-proton singlet found at 6.52 
ppm. A methine proton of C8 was assigned to one-proton singlet found at 7.13 ppm. 
A one-proton, doublet with at 7.24 ppm was assigned to the aromatic methine of C12 
(or H-12). A doublet was assigned to a proton attached to nitrogen of acetamide (NH-
COCH3) found at 7.48 ppm that is adjacent to C7 (Figure 2.26). 
Additionally, 13C NMR spectrum showed signals from all the carbon atoms.  















































Figure 2. 27 13C NMR with assignments (ppm values) and atomic numbering. 
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A DEPT experiment differentiated the methyl, methylene and methine carbons from 
the remaining quaternary carbon group signals. A positive signal at 23.02 ppm was 
assigned to the methoxy C14 carbon. A methylene CH2 and a negative signal was 
assigned to C5 carbon at 30.16 ppm. Three negative signals at 33.19 and 48.61 ppm 
were assigned to methylene CH2. A negative signal at 37.35 ppm was assigned to a 
methylene of C6 carbon. A positive signal of a methine carbon, C7 was found at 51.89 
ppm. Three positive signals of the three methyl carbons C3, C2 and C1 were found at 
56.12 ppm, 61.27 ppm and 61.44 ppm respectively. A negative signal of methylene at 
58.85 ppm was assigned to CH2 adjacent to N-CH2. A positive signal of alpha carbon 
C4’ (CH-OH) of hydroxypiperidine was found at 70.40 ppm. A positive signal of a 
methine carbon assigned to C4 was found at 107.30 ppm. A positive signal of the 
methine carbon of C11 was found at 112.15 ppm. A positive signal of the methine 
carbon of C8 was found at 125.19 ppm. A positive signal was assigned to methine CH 
carbon of C12 found at 137.20 ppm. The remaining quaternary carbon signals of 
colchicine (ring A, B and C) were found at 126.57, 129.10, 134.55, 141.51, 149.58, 
151.25, 152.76 and 154.97 ppm. A quaternary carbon of carbonyl group of C9 and 
C13 (acetamide) was found at 178.13 and 169.96 ppm respectively (Figure 2.27).  
 




























Reagents and conditions: (i) (R)-3-(Boc-aminopyrrolidine), DMF, rt, 24 h. 




To synthesise AM5 [Colchicine-(R)-3-(Boc-aminopyrrolidine)] colchicine was 
conjugated with a diamine (R)-3-(Boc-aminopyrrolidine in DMF as a solvent (Figure 
2.28). The reaction mixture was stirred and kept for 24 hours at room temperature. 
The progress of the reaction was monitored by TLC which showed completion of the 
reaction with a new yellow spot in the product lane running higher than the starting 
material (colchicine) reference. The excess amount of DMF and unreacted diamine 
was removed by Solvent extraction (chloroform/water) and dried by adding anhydrous 
sodium sulfate to remove moisture content. Crude product (AM5) was purified by silica 
gel column chromatography [chloroform: methanol: acetic acid, 9:1: 1 ml] to elute out 
the pure AM5 compound. All the fractions containing pure AM5 (confirmed by TLC) 
were eluted, combined and filtered to remove silica and evaporated to reduce the 
volume, cooled over ice bath and finally diethyl ether was added into the mixture to 
get a yellow precipitate of Col-(R)-3-Boc-amino pyrrolidine (AM5). The precipitate was 
filtered and dried to get yellow solid AM5 in a good yield. 
The structure of the compound was confirmed by its 1H NMR spectrum.  

























































A nine-proton singlet at 1.49 ppm was assigned to three methyl CH3 of Boc group. A 
three-proton multiplet at 1.70-1.90 ppm was assigned to a methylene of N-CH2-CH2 
and one of the CH of C6. A three-proton singlet was assigned to the methyl group of 
acetamide at 2.04 ppm. A proton multiplet was assigned to one of CH of C6 at 2.28 
ppm. A two-proton multiplet at 2.40 ppm was assigned to the methylene CH2 of C5. A 
three protons singlet at 3.60 ppm was assigned to the methoxy group of C1 (C1-
OCH3). A four-proton multiplet was assigned to two of the methylene (CH2) adjacent 
to N (2 x N-CH2) at 3.71-3.88 ppm. A three-proton singlet at 3.90 ppm was assigned 
to the methyl of C3. A three-proton singlet of the methyl of C2 were found at 3.96 ppm. 
A proton multiplet at 4.32 ppm was assigned to the methine CH attached to Boc-NH-
CH. A proton multiplet at 4.62 ppm was assigned to methine of C7 (H7) adjacent to 
acetamide CH-NHCOCH3. A one-proton singlet was assigned to NH adjacent to Boc 
at 4.81 ppm. One-proton doublet at 6.39 ppm was assigned to the aromatic of H-11 
(C11) proton. A methine proton of C4 was assigned to one-proton singlet found at 6.53 
ppm. A methine proton of C8 and a proton attached to nitrogen of acetamide (NH- 
COCH3) was assigned to a two-proton multiplet found at 7.15-7.23 ppm. A one-proton, 
doublet with at 7.27 ppm was assigned to the aromatic methine of C12 (or H-12) 
(Figure 2.29).  
Additionally, 13C NMR spectrum showed signals from all the carbon atoms.  




















































Figure 2. 30 13C NMR with assignments (ppm values) and atomic numbering for AM5. 
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A DEPT experiment differentiated the methyl, methylene and methine carbons from 
the remaining quaternary carbon group signals. A positive signal at 23.06 ppm was 
assigned to the methoxy C14 carbon. A positive signal at 28.40 ppm was assigned to 
three methyl of Boc. A methylene CH2 and a negative signal was assigned to C5 
carbon at 30.16 ppm. Three negative signals at 31.42 and 48.80 and 55.89 ppm were 
assigned to methylene CH2. A negative signal at 37.41 ppm was assigned to a 
methylene of C6 carbon. A positive signal of a methine carbon, C7 was found at 51.91 
ppm. Three positive signals of the three methyl carbons C3, C2 and C1 were found at 
56.12 ppm, 61.27 ppm and 61.42 ppm respectively. A positive signal of a methine 
carbon assigned to C4 was found at 107.31 ppm. A positive signal of the methine 
carbon of C11 was found at 111.73 ppm. A positive signal of the methine carbon of 
C8 was found at 126.52 ppm. A positive signal was assigned to methine CH carbon 
of C12 found at 136.97 ppm. The remaining quaternary carbon signals of colchicine 
(ring A, B and C) were found at 129.44, 134.52, 141.59, 149.70, 151.36, 152.80 and 
154.79 ppm. A quaternary carbon of carbonyl group of C9 and C13 (acetamide) and 
carbonyl carbon adjacent to Boc was found at 169.77 and 155.37 and 178.80 ppm 
respectively (Figure 2.30) 
 




































Reagents and conditions: (i) TFA, rt, 30 min. 
Figure 2. 31 Synthesis of Colchicine-(R)-3-(aminopyrrolidine)-TFA (AM6) from AM5 (Colchicine-(R)-3-




To synthesise AM6 [Colchicine-(R)-3-amino-Pyrrolidine-TFA] (a TFA salt) Boc group 
was removed from AM5 (Colchicine-(R)-3-(Boc-amino) pyrrolidine) by reacting AM5 
with TFA (trifluoroacetic acid) for 30 minutes at room temperature. The reaction 
mixture was then evaporated to remove TFA by addition of ethanol that would help in 
evaporation of TFA from the mixture. The AM6 compound was filtered, dried to get 
solid precipitates of AM6 compound (Figure 2.31). 
AM6 was characterised by MS (ESI+) mass spectrum that showed a signal at m/z 
454.23 Da in (M+H)+  for the cationic species [C25H32N3O5]+  and its sodium adduct 
476.21 (M+Na)+ and confirmed the molecular mass of 567.22 Da because in positive 
ion mode it only read positive ion specie and TFA was negatively charged molecule. 
(Figures 2.32 and 2.33) 
   




   
Figure 2. 33 Comparison of the observed data with the theoretical isotope model of AM6. 
The structure of the compound was also confirmed by its 1H NMR spectrum. 



























































A proton multiplet was assigned to one of methylene protons at C6 at 1.80 ppm. A 
three-proton singlet was assigned to the methyl group of acetamide at 1.92-2.07 ppm. 
A three-proton multiplet at 2.23 ppm was assigned to a methylene of N-CH2-CH2 and 
one of the CH of C6. A two-proton multiplet at 2.57 ppm was assigned to the methylene 
CH2 of C5. A three protons singlet at 3.51 ppm was assigned to the methoxy group of 
C1 (C1-OCH3). A two-proton multiplet at 3.70 ppm was assigned to methylene 
adjacent to nitrogen (N-CH2). A three-proton singlet at 3.78 ppm was assigned to the 
methyl of C3. A three-proton singlet of the methyl of C2 were found at 3.82 ppm. A 
three-proton multiplet at 3.85-3.98 ppm was assigned to a methylene (C10-N-CH2) 
and a methine next to NH3 (CH-NH3). A proton multiplet at 4.32 ppm was assigned to 
methine of C7 (H7) adjacent to acetamide CH-NHCOCH3. One-proton doublet at 6.44-
6.46 ppm was assigned to the aromatic of H-11 (C11) proton with J= 12 Hz. A methine 
proton of C4 was assigned to one-proton singlet found at 6.74 ppm. A proton singlet 
at 6.87 ppm was assigned to methine of C8. A one-proton, doublet with at 7.03 -7.07 
ppm was assigned to the aromatic methine of C12 (or H-12) with J= 12 Hz. A three-
proton multiplet was assigned to three hydrogen atoms of NH3 at 8.19 ppm. A proton 
doublet at 8.54 ppm was assigned to NH of acetamide (Figure 2.34).  
Additionally, 13C NMR spectrum showed signals from all the carbon atoms.  



























































A DEPT experiment differentiated the methyl, methylene and methine carbons from 
the remaining quaternary carbon group signals. A positive signal at 22.49 ppm was 
assigned to the methoxy C14 carbon. A methylene CH2 and a negative signal was 
assigned to C5 carbon at 28.39 ppm. Three negative signals at 29.48, 47.81 and 53.53 
ppm were assigned to methylene CH2. A negative signal at 36.48 ppm was assigned 
to a methylene of C6 carbon. A positive signal was found at 49.37 for methine. A 
positive signal of a methine carbon, C7 was found at 50.80 ppm. Three positive signals 
of the three methyl carbons C3, C2 and C1 were found at 55.78 ppm, 60.52 ppm and 
60.62 ppm respectively. A positive signal of a methine carbon assigned to C4 was 
found at 107.65 ppm. A positive signal of the methine carbon of C11 was found at 
110.86 ppm. A positive signal of the methine carbon of C8 was found at 125.50 ppm. 
A positive signal was assigned to methine CH carbon of C12 found at 135.94 ppm. 
The remaining quaternary carbon signals of colchicine (ring A, B and C) were found 
at 126.14, 128.43, 134.40, 140.69, 149.25, 150.44, 152.32 and 153.67 ppm. A part of 
quartet carbon was assigned to 158.09. CF3 carbon was assigned to 158.54 ppm. A 
quaternary carbon of carbonyl group of C13 (acetamide) and C9 were found at 168.39 
and 177.67 ppm respectively (Figure 2.35). 
 


































Reagents and conditions: (i) TPP (triphenylphosphonium bromide) PyBOP, DIPEA, HOBt, DMF, rt, 24h. 
Figure 2. 36 Synthesis of Col-(R)-3-aminopyrrolidine-TPP (AM7) from AM6 (Col-(R)-3-
aminopyrrolidine-TFA) (Addition of TPP). 
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To synthesise AM7 (Col-(R)-3-aminopyrrolidine-TPP), AM6 (Col-(R)-3-
aminopyrrolidine-TFA) was conjugated with TPP by an amidation reaction between 
carboxylic acid group (COOH) of TPP and amino (NH) group of (R)-3-aminopyrrolidine 
in AM6 by a standard coupling method of peptides in DMF. In the reaction the 
carboxylic acid group of TPP was activated by PyBOP, DIPEA and HOBt through an 
esterification reaction to synthesise or produce the title compound AM7, a TPP 
conjugate prodrug (Figure 2.36). 
Activated TPP was added to AM6 in DMF and reaction was set for 24 hours at room 
temperature. The progress of the reaction was monitored by TLC. TLC showed 
successful formation of AM7 product as yellow spot running higher than AM6 (starting 
material) in the product lane. Once the reaction was completed solvent extraction 
(Chloroform/water) was performed to remove excess TFA salt, unreacted TPP and 
DMF. Anhydrous sodium sulfate was added to mixture and stirred to remove moisture. 
The crude compound AM7 was purified by silica gel chromatography, the mobile 
phase (chloroform: methanol, 9:1) was used to elute AM7. All the fractions containing 
AM7 (confirmed by TLC) were eluted, combined, filtered to remove silica, evaporated 
to reduce the volume, cooled over ice bath and finally diethyl ether was added to get 
precipitates of pure AM7 compound in a good yield. 
AM7 was characterised by MS (ESI+) mass spectrum that showed a signal at m/z 
798.36 Da in (M+H)+  for the cationic species [C48H53N3O6P]+  and confirmed the 
molecular mass of 877.29 Da that includes the mass of bromide ion an anionic specie. 




Figure 2. 37 ESI (+) Mass spectrum of AM7 (Col-(R)-3-aminopyrrolidine-TPP). 
 
Figure 2. 38 Comparison of the observed data with the theoretical isotope model for AM7. 
The structure of the compound was also confirmed by its 1H NMR spectrum. 
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An eight-proton multiplet was assigned to two methylene (P-CH2-CH2-CH2), a methyl 
of acetamide (NHCO-CH3) and a hydrogen of C6 (CH) at 1.50-1.85 ppm. A three-
proton multiplet at 2.01-2.23 ppm was assigned to a methylene of N-CH2-CH2 and one 
of the CH of C6. A two-hydrogen triplet was assigned to the methylene next to carbonyl 
group (CH2-COO) at 2.34 ppm. A two-proton multiplet at 2.50 ppm was assigned to 
the methylene CH2 of C5. A two-proton singlet was assigned to the methylene attached 
to P (P-CH2) at 3.02 ppm. A three protons singlet at 3.50 ppm was assigned to the 
methoxy group of C1 (C1-OCH3). A two-proton multiplet at 3.60 ppm was assigned to 
methylene adjacent to nitrogen (C10-N-CH2). A three-proton singlet at 3.80 ppm was 
assigned to the methyl of C3. A three-proton singlet of the methyl of C2 were found at 
3.85 ppm. A three-hydrogen multiplet was assigned to the methylene N-CH2-CH2 and 
methine attached to TPP (CH-TPP) at 4.20 ppm. A proton multiplet at 4.39 ppm was 
assigned to methine of C7 (H7) adjacent to acetamide CH-NHCOCH3. One-proton 
doublet at 6.35 ppm was assigned to the aromatic of H-11 (C11) proton with J= 11 Hz. 
A methine proton of C4 was assigned to one-proton singlet found at 6.71 ppm. A 
proton singlet at 6.85 ppm was assigned to methine of C8. A one-proton, doublet with 
at 7.00 ppm was assigned to the aromatic methine of C12 (or H-12) with J= 11 Hz. A 
fifteen hydrogen multiplet was assigned to TPP at 7.80 ppm. A proton doublet at 8.15 
ppm was assigned to the NH of acetamide.  
 





























Reagents and conditions: (i) TPP, DCC, DMAP, CH2Cl2 (dichloromethane), rt, 24 h. 
Figure 2. 39 Synthesis of AM8 (Colchicine-4-hydroxypiperidine-TPP) from AM3 (Colchicine-4-
hydroxypiperidine) (Addition of TPP) 
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AM8 (Colchicine-4-hydroxypiperidine-TPP) was synthesised by conjugating TPP with 
AM3 (Colchicine-4-hydroxypiperidine) by an esterification reaction between carboxylic 
acid group (COOH) of TPP and hydroxyl (OH) group of 4-hydroxypiperidine in AM3, 
where carboxylic group of TPP was activated by DMAP (as a catalyst base) and DCC 
as a coupling enhancer. These bases induce coupling between an alcohol and a 
carboxyl group and initiate formation of an active ester (Figure 2.39).   
Activated TPP was added to AM3 dissolved in dichloromethane (CH2Cl2). The 
progress of the reaction was monitored by TLC. Once the reaction was completed 
solvent extraction (chloroform/water) was performed to remove extra TPP and to 
convert DCC into DCU that then was removed by filtration. TLC was performed that 
showed successful formation of AM8 product as yellow spot running lower than AM3 
(starting material) in the product lane. The crude compound AM8 was purified by silica 
gel chromatography by mobile phase dichloromethane, dichloromethane: methanol, 
9:1 and 4:1 with order of increased polarity. All the fractions containing AM8 (confirmed 
by TLC) were eluted but some solid crystals of DCU was present in two of the fractions. 
The fractions of compound AM8 were filtered to remove silica and DCU, evaporated 
to reduce the volume, cooled over ice bath and finally diethyl ether was added to get 
precipitates of pure AM8 compound in a good yield. 
AM8 was characterised by MS (ESI+) mass spectrum that showed a signal at m/z 
813.36 Da in (M+H)+ for the cationic species [C49H54N2O7P]+  and confirmed the 





Figure 2. 40 ESI (+) Mass spectrum of AM8 (Col--4-hydroxypiperidine-TPP). 
 
Figure 2. 41 Comparison of the observed data with the theoretical isotope model of AM8 
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Figure 2. 42 1H NMR assignments (ppm values) and atomic numbering for AM8.  
 
An eight-proton multiplet was assigned to two methylene (P-CH2-CH2-CH2) at 1.49-
1.63 ppm. A four-proton singlet was assigned to a methyl of acetamide (NHCO-CH3) 
and a hydrogen of C6 (CH) at 1.84 ppm. A two-proton multiplet at 2.00-2.04 ppm was 
assigned to a methylene of N-CH2-CH2. A two-hydrogen triplet was assigned to the 
methylene next to carbonyl group (CH2-COO) at 2.42 ppm. A two-proton multiplet at 
2.51 ppm was assigned to the methylene CH2 of C5. A two-hydrogen multiplet was 
assigned to the methylene N-CH2-CH2 at 3.12-3.25 ppm. A two-proton multiplet was 
assigned to the methylene attached to P (P-CH2) at 3.38-3.43 ppm. A three protons 
singlet at 3.52 ppm was assigned to the methoxy group of C1 (C1-OCH3). A four-
proton multiplet at 3.64 ppm was assigned to two methylene adjacent to nitrogen (2xN-
CH2). A three-proton singlet at 3.78 ppm was assigned to the methyl of C3. A three-
proton singlet of the methyl of C2 were found at 3.83 ppm. A one-proton multiplet was 
assigned to CH adjacent to OCO at 4.28-4.36 ppm. A proton multiplet at 4.88 ppm 
was assigned to methine of C7 (H7) adjacent to acetamide CH-NHCOCH3. A methine 
proton of C4 was assigned to one-proton singlet found at 6.76 ppm. One-proton 
doublet at 6.88 ppm was assigned to the aromatic of H-11 (C11) proton with J= 11 Hz. 
A proton singlet at 6.97 ppm was assigned to methine of C8. A one-proton, doublet 
with at 7.04-7.08 ppm was assigned to the aromatic methine of C12 (or H-12) with J= 
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11 Hz. A fifteen hydrogen multiplet was assigned to TPP at 7.82 ppm. A proton doublet 
at 8.56 ppm was assigned to NH of acetamide (Figure 2.42).  
 
Additionally, the 13C NMR spectrum showed signals from all the carbon atoms. 








































Figure 2. 43 13C NMR with assignments (ppm values) and atomic numbering for AM8. 
 
A DEPT experiment differentiated the methyl, methylene and methine carbons from 
the remaining quaternary carbon group signals. A positive signal at 22.49 ppm was 
assigned to the methoxy C14 carbon. Seven negative signals at 24.43, 25.30, 30.35, 
32.81, 33.31, 36.11 and 45.25 ppm were assigned to methylene CH2. A positive signal 
was found at 50.86 ppm for methine. Three quaternary carbon signals were found at 
55.82 ppm 60.64 ppm and 60.69 ppm. A positive signal for the methine was found at 
69.30 ppm. A positive signal of a methine carbon assigned to C4 was found at 107.70 
ppm. A positive signal of the methine carbon of C11 was found at 117.88 ppm. Two 
signals were found at 119.02 and 125.71 (unspecified). A positive signal of the methine 
carbon of C8 was found at 128.41 ppm. Two positive signals for ortho and meta 
methine of TPP were found at 130.14 ppm and 130.31 ppm. Two positive signals for 
ortho and meta methine of TPP were found at 133.46 ppm and 130.60 ppm. A positive 
signal of the para methine of TPP was found at 134.33. A positive signal was assigned 
to methine CH carbon of C12 found at 134.92 ppm. The remaining quaternary carbon 
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signals of colchicine (ring A, B and C) were found at 119.02 ppm, 125.71 ppm, 132.59 
ppm, 140.68 ppm, 149.03 ppm, and 150.44 ppm (Figure 2.43). 
 





























Reagents and conditions: (i) TPP, DCC, DMAP, CH2Cl2 (dichloromethane), rt, 24 h. 
Figure 2. 44 Synthesis of Colchicine-(R)-3-Pyrrolidinol)-TPP (AM9) from AM4 (Colchicine-(R)-3-
Pyrrolidinol) 
 
AM9 (Colchicine-(R)-3-Pyrrolidinol)-TPP) was synthesised by conjugating TPP with 
AM4 (Colchicine-(R)-3-Pyrrolidinol) by an esterification reaction between carboxylic 
acid group (COOH) of TPP and hydroxyl (OH) group of (R)-3-pyrrolidinol in AM4, 
where carboxylic group of TPP was activated by DMAP (as a catalyst base) and DCC 
as a coupling enhancer (Figure 2.44).  
Activated TPP was added to AM4 dissolved in dichloromethane (CH2Cl2). The 
progress of the reaction was monitored by TLC. Once the reaction was completed 
solvent extraction (chloroform/water) was performed to remove extra TPP and to 
convert DCC into DCU that then was removed by filtration. TLC was performed that 
showed successful formation of AM9 product as yellow spot running lower than AM4 
(starting material) in the product lane. The crude compound AM9 was purified by silica 
gel chromatography by mobile phase dichloromethane, dichloromethane: methanol, 
9:1 and 4:1. All the fractions containing AM9 (confirmed by TLC) were eluted, filtered 
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to remove silica and DCU, evaporated to reduce the volume, cooled over ice bath and 
finally diethyl ether was added to get precipitates of pure AM9 compound in a good 
yield. AM9 was characterised by MS (ESI+) mass spectrum that showed a signal at 
m/z 799.34 Da in (M+H)+  for the cationic species [C48H52N2O7P]+  and confirmed the 
molecular mass of 878.27 Da that includes the mass of anionic bromide ion. (Figures 
2.45 and 2.46). 
 




Figure 2. 46 Comparison of the observed data with the theoretical isotope model of AM9. 



























































A two-proton multiplet was assigned to the methylene group (COCH2-CH2-CH2-CH2-
P) at 1.59 ppm. A two-proton multiplet was assigned to the methylene (COCH2-CH2-
CH2-CH2-P) at 1.73 ppm. A four-proton singlet was assigned to a methyl of acetamide 
(NHCO-CH3) and a hydrogen of C6 (CH) at 1.85 ppm. A three-proton multiplet was 
assigned to the methylene N-CH2-CH2 and CH of C6 at 2.14-2.22 ppm. A two-
hydrogen triplet was assigned to the methylene next to carbonyl group (CH2-COO) at 
2.40 ppm. A two-proton multiplet at 2.51 ppm was assigned to the methylene CH2 of 
C5. A two-proton multiplet was assigned to the methylene attached to P (P-CH2) at 
3.34 ppm. A three protons singlet at 3.49 ppm was assigned to the methoxy group of 
C1 (C1-OCH3). A four-proton multiplet at 3.56-3.66 ppm was assigned to two 
methylene adjacent to nitrogen (2 x N-CH2). A three-proton singlet at 3.78 ppm was 
assigned to the methyl of C3. A three-proton singlet of the methyl of C2 were found at 
3.83 ppm. A proton multiplet at 4.28-4.37 ppm was assigned to methine of C7 (H7) 
adjacent to acetamide CH-NHCOCH3. A one-proton singlet was assigned to CH 
adjacent to OCO at 5.27 ppm. One-proton doublet at 6.39-6.43 ppm was assigned to 
the aromatic of H-11 (C11) proton with J=11 Hz. A methine proton of C4 was assigned 
to one-proton singlet found at 6.74 ppm. A proton singlet at 6.83 ppm was assigned to 
methine of C8. A one-proton, doublet with at 6.99-7.03 ppm was assigned to the 
aromatic methine of C12 (or H-12) with J=11 Hz. A fifteen hydrogen multiplet was 
assigned to TPP at 7.76 -7.93 ppm. A proton doublet at 8.50-8.52 ppm was assigned 











 Distribution Coefficient Studies 
 
The physicochemical properties of novel colchicine derivatives (AM1, AM3, AM4, AM5 
and AM6) and TPP-conjugated colchicine derivatives (AM2, AM7, AM8 and AM9) 
were studied to determine the distribution coefficient. 
Distribution coefficient is an important parameter that determines if the given drug 
compound is hydrophobic “water hating” or hydrophilic “water loving” in nature. This is 
the crucial predictor of drug distribution inside the body. Pharmacokinetics studies 
reveals that hydrophilic compounds will most likely to be distributed in the aqueous 
compartments of the body such as blood or plasma, whereas a hydrophobic 
compound will be distributed in the lipid or fatty compartments of the body such as 
lipid bilayer cellular membrane (Markovsky et al., 2012).  
Distribution coefficient define as the ratio of the concentration of a drug molecule or a 
compound (solute) in a mixture of two immiscible solvents at equilibrium. It is 
represented by log D or log P. However, log P only predicts partition of uncharged or 
unionised or neutral drug molecule (solute molecules) therefore it is not a true 
determinant of hydrophilicity or hydrophobicity of an ionised species inside a body 
where pH is always changing. Whereas, the distribution coefficient, log D, accurately 
determines concentration of ionised and unionised drug moieties and is pH dependent. 
A polar or hydrophilic compound would always favour aqueous or a polar phase such 
as PBS buffer (pH. 7.4) and a non-polar or hydrophobic compound always favours 
non-polar or an organic phase such as octanol (Andrés et al., 2015)(Pajouhesh and 
Lenz, 2005). 
Octanol is used as an organic solvent (phase) in distribution coefficient experiment 
because its 8-carbon atoms are highly hydrophobic and are like hydrophobic lipid 
bilayer of cell membrane according to the biological data obtained in vivo. And, it has 
a hydrophilic hydroxyl group (OH) that favours hydrogen bonding with solute. So, it 
gives the closest balance to that found in human cell membrane. PBS represents the 
aqueous zone of the body such as blood plasma. Hence the distribution coefficient 
can be a true predictor of main elements of ADME that is, absorption, distribution and 
elimination (Hinderliter and Saghir, 2014).  
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As the main drug target of the current study is mitochondria, an important organelle of 
the cell with lipid bilayer membrane and it was already discussed in the introduction of 
this project that TPP-conjugates of colchicine derivatives needs to be hydrophobic or 
lipophilic in order to cross lipid bilayer of cell membrane and mitochondrial membrane. 
So, distribution coefficient experiment was performed to check whether TPP-linked 
colchicine derivatives (AM2, AM7, AM8 and AM9) are hydrophobic in nature in 
comparison with their non-TPP-linked colchicine derivatives (AM1, AM3, AM4, AM5 
and AM6). 
 
 Determination of distribution coefficient (Log D) method 
 
Distribution coefficient experiments were performed and log D results for AM 
compounds (AM1-AM9) were obtained by using the shake-flask octanol/PBS partition 
coefficient method. To plot the calibration curves for each compound, two sets of 
cuvettes were prepared at different concentration ranging from 0 µM to 25 µM for all 
the compounds (AM1-AM9). In one set of cuvettes (5 in total) the compound was 
diluted in PBs (buffer, pH 7.4) and in other set the drug compound was diluted with 
octanol to get the specific concentration. The absorbance reading was in a range of 
0-0.85 in case of octanol calibration for all the drug compounds and graph showed a 
linear line of best fit for all the compounds. The equations derived from octanol 
calibration curves are as follows: AM1 (y=0.0237x-0.003), AM2 (y=0.0201x+0.003), 
AM3 (y=0.0188x+0.0066), AM4 (y=0.0337x+0.0076), AM5 (y=0.0293x+0.0041) AM6 
(y= 0.0164x+0.0081), AM7 (y=0.0097x+0.0019), AM8 (y=0.0154x+0.0006) and AM9 
(y=0.0199x+0.0059) (Appendix figures A.1.1 to A.1.5).   
For PBS calibration curves, the absorbance reading was in a range of 0-0.89 for all 
the drug compounds and graph showed a linear line of best fit for all the compounds. 
(Figures calibration curves). The equations derived from PBS calibration curves are 
as follows: AM1 (y= 0.0258x + 0.0046), AM2 (y = 0.0208x + 0.0034), AM3 (y = 0.0213x 
+ 0.005), AM4 (y = 0.0353x + 0.0063), AM5 (y = 0.029x + 0.0104), AM6 (y = 0.0181x 
- 0.0017), AM7 (y = 0.0097x + 0.0019), AM8 (y = 0.0139x + 0.0019) and AM9 (y = 
0.0199x + 0.005) (Appendix Figures A.1.1 to A.1.5). 
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The absorbance readings from distributed samples of AM1-AM9 are listed in the tables 
(Appendix Table A.2.1-A.2.9), using these absorbance values, equation obtained 
from calibration curve data and considering the dilution factor for each concentration 
the log D value were calculated for all the colchicine derivatives and their TPP-
conjugates using the equation given below: 
        
 
Log D values for all aminocolchicine derivatives were AM1 (log D=1.69) (Appendix 
Table A.2.1), AM3 (log D=1.64) (Appendix Table A.2.3), AM4 (log D=1.65) 
(Appendix Table A.2.4) AM5 (log D=1.63) (Appendix Table A.2.5) and AM6 (log 
D=1.28) (Appendix Table A.2.6).  
Table 2. 1 Log D values for aminocolchicine derivatives (Appendix A.2.1-Appendix A.2.6). 
Amino-colchicine derivatives Log D values 
AM1 1.69  0.06 
AM3 1.64  0.02   
AM4 1.65  0.04 
AM5 1.63  0.005 
AM6 1.28  0.03 
 
Results were as expected as their clinical comparator colchicine itself has a log P 
value of 2.34 making it a lipophilic compound (Swissadme.ch, 2019).  
All the aminocolchicine derivatives were mainly partitioned in the octanol (organic) 
layer, since these compounds predominantly found in organic layer that means they 
are lipophilic or hydrophobic in nature. Ionization of the compounds greatly affects 
octanol/water partitioning. Where AM1 emerged as most hydrophobic agent in 
aminocolchicine derivatives with log D value of 1.69. Lipophilicity or hydrophobicity is 
low under 12 pH because at this pH majority of the compound exist in ionized form. 
Negative log D values (-1.44 to 0) in the physiological pH range (1-8) lead us to 
conclude that the compound has higher water solubility or is hydrophilic/lipophobic in 
log D oct/water = log
[solute]octanol
[solute]ionised water  + [solute]neutal water
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nature that means poor membrane permeability. Positive log D values (1-5) predict 
higher lipophilicity of drug compounds (Bhal, 2007; Lipinski, 2000). 
 
The log D values for TPP-conjugated aminocolchicine were; AM2 (1.34) (Appendix 
Table A.2.2), AM7 (0.72) (Appendix Table A.2.7), AM8 (1.28) (Appendix Table 
A.2.8) and AM9 (1.37) (Appendix Table A.2.9).  
 
Table 2. 2 Log D values for TPP-conjugated aminocolchicine (Appendix A.2.2-Appendix A.2.9). 
Tpp-conjugated aminocolchicine  Log D  
AM2 1.34  0.26 
AM7 0.72  0.11 
AM8 1.28  0.05 
AM9 1.37  0.04 
 
Results demonstrated that TPP-conjugated aminocolchicine derivatives were also 
predominantly found in octanol layer hence proved to be hydrophobic/lipophilic in 
nature, but these TPP-conjugates are less hydrophobic in comparison of their non-
conjugated compounds. This was unexpected because compounds with TPP 
supposed to be more hydrophobic due to presence of lipophilic cation TPP. AM7 (a 
TPP-conjugated aminocolchicine derivative of AM6) turned out to be the least 
hydrophobic compound among all the amino-colchicine derivatives with a log D value 
of 0.72. 
However, all amino-colchicine derivatives with or without TPP showed a moderate 
degree of hydrophobicity except AM7 (0.72), that predicted easy passage of these 
compounds from cell and mitochondrial lipid bilayer membranes. 
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 Effect of Novel targeted anthelmintic prodrugs on C. elegans 
 
TPP is a lipophilic cationic drug delivery vehicle that directs drug molecules to the 
target site (mitochondria) when conjugated with the compounds (drug compounds) 
due to its unique characteristics such as delocalised positive charge and its lipophilicity 
(as discussed previously in detail in section 1.4.2.1)  that not only attracts TPP base 
compounds towards the matrix of mitochondria but also ensure the easy passage from 
the lipid bilayer of cell and mitochondrial membrane (Finichiu et al., 2013) 
In the current study TPP-conjugated colchicine derivatives were synthesised as 
potential anthelmintic agents to target colchicine derivatives (active drug) to the target 
site i.e. “the worm’s mitochondria”. In doing so, it was anticipated that they not only 
provide targeted delivery to the site and possibly circumvent the resistance against 
colchicine but also reduce the toxic effects to the host by achieving selectivity. In order 
to prove this concept and to prove the efficacy of TTP-conjugated compounds (AM2, 
AM7, AM8 and AM9) in comparison with the non-conjugated compounds (AM1, AM3, 
AM4, AM5 and AM6), C. elegans worm was selected as a model organism because 
of its close resemblance with helminths parasite to see the potential of these drugs as 
novel anthelmintic agents. 
 
 C. elegans viability asaay 
 
For this purpose, L4 worms were chosen from wild type C. elegans synchronised 
population and were exposed to different concentrations of Colchicine derivatives and 
their TPP-conjugates to establish comparison. Two novel colchicine derivatives AM1 
and AM2 were chosen for the experiment. Where AM1 (Col-Pro) is the colchicine 
derivative with prolinol and AM2 (Col-Pro-TPP) is an ester-linked TPP-conjugate of 
AM1. L4 were exposed to different concentrations of AM1 and AM2 for 24 hours at 
start (n=1 experiment). The result demonstrated that at 100 µM, TPP-conjugate, AM2 
showed 2% worm survival as compared with its non-conjugated form AM1 (Figure 
2.49). Whereas, 10 µM, 1 µM, and 0.1 µM of both AM1 and AM2 did not appear to be 
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different from each other and more than 96% worm survival was monitored after 
treatment exposure.  
             
Figure 2. 48 % survival of C. elegans for AM1 and AM2 at different concentrations (0.1 µM, 1 µM, 10 
µM   and 100 µM in the presence of negative controls (S. medium control and DMSO control) at 22h. 
% survival of C.elegans was calculated by considering number of live worms and divided by sum of live 
and dead worms multiplied by 100 to get % of survival. The experiment was repeated in triplicates with 
n=3. 
The aim of the results described in the worm viability assay was to enlighten the 
efficacy of TPP-conjugated colchicine derivatives in anthelmintic therapy. AM2 (a TPP-
conjugate, a magic bullet) most likely to possess anthelmintic activity given the fact 
that 98% worms died in the first exposure (n=1) for 24 hours at 100 µM (Figure. 2.48). 
Results have shown a trend of toxicity of TPP conjugated prodrug AM2 as 2% worm’s 
survival in comparison with AM1 with 96% worm survivals. It suggested that TPP is 
likely responsible for the results described in the figure due to its high affinity for the 
mitochondria because of the ability of TPP to cross membrane of a cell and 
mitochondria without needing a transporter mechanism (Ross et al., 2005). It allows 
easy a quick uptake of AM2 compound in the worm’s mitochondria where TPP-
conjugate would release active drug following cleavage of ester bond between TPP 
and Colchicine derivative by worm esterase. This result gives us a strong ground for 
proof of concept for TPP-conjugated colchicine derivatives being developed as 
promising agents in anthelmintic therapy.  
However, when the same experiment was performed in n=3, and with increased time 
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preliminary study. There was a level of toxicity from these agents towards C. elegans 
worms and this was approaching significance. 
Another study was conducted on the same agents AM1 and AM2 where behavioural 
assay was performed. In the behavioural assay, worm viability was tested in terms of 
motility measurement of the worms after exposing worms to treatment (AM1 & AM2) 
with the negative controls (S. medium and DMSO). Motility was measured by counting 
the total number of turns (bends) by an individual worm per minutes. (BDPM). Results 
were recorded at 2 hours and 24 hours and data was presented in mean of the total 
number of body-turns per minute/worm. The experiment was performed in n=4. The 
Results obtained from the experiment indicated a difference in worm motility, however 
statistical significance (P<0.05) was not achieved for both AM1 and TPP-conjugate 
AM2, the effects were time dependent i.e. increased effect after 24-hour exposure.  
Results showed that motility of worms decreased after 24-hour exposure for both the 
agents and AM2 the TPP-conjugated prodrug is more potent in terms of decreasing 
motility and viability of worms as compared to AM1 as shown in the figure. These 
results further provided support for our concept of TPP-conjugated magic bullets 
having the potential to be targeted novel anthelmintic prodrugs (Figure 2.49). 
        
Figure 2. 49 The comparison between effects AM1 and TPP-conjugate AM2 on worm’s viability in terms 
of motility at 2 h and 24 h exposure, with both negative controls; s. medium and DMSO. Motility was 
measured by total number of turns per individual worm per minute, data shown in mean of number of 
turns per minute. Experiment was performed in duplicate with n=4. (Adopted from the results provided 
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The same experiment was also performed on other two agents of the AM series:  AM6 
(Colchicine-(R)-3-amino-Pyrrolidine-TFA) and its TPP conjugate AM7 (Colchicine-(R)-
3-amino-Pyrrolidine-TPP) and it was decided to increase the exposure time to 48 
hours this time as it was shown in the results that motility was decreased but worms 
were not dead or immobilised. Results obtained from the experiment showed that both 
AM6 and its TPP conjugate reduced the motility of the worms, so they have the 
potential to affect the viability of the worms. However, the theory of increasing time 
exposure was proven wrong because at 24 hours the motility of the worms was lowest 
(reduced) but after 48 hours exposure of the treatments the motility increased and also 
the worms count was highest at the point. These results also showed that prolong time 
exposure of these agents can lead to decrease in their effects on the viability of worms 
(Figure 2.50).  
 
 
Figure 2. 50 The comparison between effects AM6 and TPP-conjugate AM7 on worm viability in terms 
of motility at 2 h, 24 h and 48 h exposure, with both negative controls; s. medium and DMSO. Motility 
was measured by total number of turns per individual worm per minute, data shown in mean of number 
of turns per minute. Experiment was performed in duplicate with n=4. (Adopted from the results provided 
by Dr. Lorna Proudfoot). 
 
All the results obtained from worm viability assay using these novel colchicine TPP- 
conjugated prodrugs demonstrated that there is a strong effect on worm viability, but 
the effect of these prodrugs decreased by the time. One possible reasoning for this is 
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parasite model can be considered for further testing on these agents to get a clear 
idea of their effect on helminth viability. C.elegans live in soil where they deal with 
extreme and constant osmotic pressure or stress. C. elegans recovered from the 
shock very quickly and return to their normal motion as the time passes. Their ability 
to survive after the shock and come out of stress is very impressive. They have ability 
to sense and reverse changes in the cell and survive extreme conditions in the 
laboratory due to their ability to adapt these changes and turgor pressure (Lamitina, 
2004). It can be possible that a strain of C. elegans is sensitive to chemical stress and 
another strain is completely resistant to the same chemical. This variation in the 
different strains of C. elegans have been studied many times to elaborate their survival 
and coma back from stress. Mutations can be developed in then c. elegans against 
toxicity of various chemicals such as toxicity produced by Zinc (Zn) (Bruinsma et al., 
2008) 
Another reason could be the solubility of these agents in solvents. Although AM1 and 
AM2 were soluble in the DMSO still some of the viability assay showed traces of solid 
crystals in the treatment wells which may have been attributable to the drugs slowly 














 Molecular Docking 
 
Technological advancements such as molecular docking, can be employed to obtain 
the atomic information of protein-ligand complex interaction and has and presented a 
new platform for the drug design and development for specific targets. It helps to 
predict the best possible interaction between drug molecules and target sites. 
Molecular docking is an efficient tool and is playing a very important significant role in 
the rationale of drug design. It is a computational way to look for a suitable ligand (a 
drug molecule) that has the suitable fit profile for the binding site (a protein molecule 
or an enzyme) in fixed orientation and in order of internal geometry. Just like a 3D 
puzzle, or ligand receptor lock and key model, where one molecule such as a drug 
molecule or a ligand has the binding affinity for the pocket of another molecule, a 
protein receptor. If the structure of the protein is known, different conformations of the 
selected ligand can be easily seen in the protein molecule (Ferreira et al., 2015; 
Guedes et al., 2014; Kholod et al., 2018).  
A preliminary study has been performed for novel amino-colchicines AM1 (Col-
Prolinol), AM3 (Col-4hydroxypiperidine), AM4 (Col-(R)-3-pyrrolidinol), AM6 (Col-
aminopyrrolidine) and a reference compound CN2 (N-deacetyl-N-(2-mercaptoacetyl)-
colchicine) that is a known tubulin binder and a colchicine binding site inhibitor (CBSI) 
(Ravelli et al., 2004). Docking studies revealed binding energies for all these 
compounds that showed these agents have binding affinity for tubulin molecule 
(Figure 2.51 & 2.52), where AM6 showed strong tubulin binding with binding energy -
9.84 KJ in comparison with the reference compound CN2 (which is a CBSI) that has 
binding energy of -9.01 Kcal/mol (Table 2.1). A negative or low energy refers to the 
strong binding of ligand into protein (receptor) pocket, means the ligand and protein 
complex is stable and most likely to interact with each other whereas a higher or 
positive binding energy means more energy needed by the complex for interaction 
hence weak binding (Ferreira et al., 2015).  





Figure 2. 51 CN2 (N-deacetyl-N-(2-mercaptoacetyl)-colchicine in complex with X-ray crystal structure 
of bovine α, β-tubulin in the colchicine binding pocket. Crystal structure obtained from the protein 
database in the pdb form.  
 
AutoDock4 software was employed to generate binding models for CN2 compound 
that is a tubulin modulator and CBSI (colchicine binding site inhibitor). Figure 2.51 
showing binding of the ligand CN2 in the tubulin molecule at the interface of chain A 
and chain B, the methoxy group on the ring A of colchicine facilitates interaction with 
CYS241 residue (please note that CYS241 residue is very important for the interaction 
in case of CBS (colchicine binding site). Ligand CN2 also showed interaction with 
residues VAL181, THR314, ASN349 and VAL315. In this picture, Line model is alpha 
and beta chain of tubulin, LIG, CN2 (ligand and its code is CN2), CYS241 (cysteine 
241 on chain B of tubulin molecule), VAL181 (Valine residue on chain A of tubulin 
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molecule), VAL315 (on chain B), ASN349 (Asparagine residue on chain B), THR314 
(Threonine residue on chain B of tubulin).VMD software has been used to create this 




Figure 2. 52 Binding model of compound AM1 (Col-Pro) (a potential tubulin modulator), in the colchicine 
binding pocket; top ranked pose.  
 
AutoDock4 results shows that AM1 binds in the same colchicine binding pocket at the 
interface of alpha and beta chains of tubulin molecule as CN2 and interacting with the 
same residues as did CN2. Here one thing is clear that we use CN2 as our reference 
compounds to compare our results with. The methoxy group on the ring A of colchicine 
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facilitates interaction with CYS241 residue (please note that CYS241 residue is very 
important for the interaction in case of CBS (colchicine binding site). Line model is 
alpha and beta chain of tubulin, LIG, AM1 (ligand and its code is AM1), CYS241 
(cysteine 241 on chain B of tubulin molecule), VAL181 (Valine residue on chain A of 
tubulin molecule), VAL315 (on chain B), ASN349 (Asparagine residue on chain B), 
THR314 (Threonine residue on chain B of tubulin). VMD software has been used to 
create this representation after obtaining docking results from AutoDock software. 
 
Table 2. 3 Binding energies of AM1, AM3, AM4, AM6 and CN2 (the reference compound).  














      
AM6 shown the lowest binding energy with -9.86 Kcal, demonstrate that it has a strong 
binding affinity for tubulin as compared to reference compound CN2 (-9.01) and AM1 
(-9.00 kCal) shown to have same binding energy as CN2; important to note here that 
both the compounds share almost same lowest binding energies (we already know 





 Conclusion & Future work: 
 
Resistance is a major issue when it comes to the efficacy of traditional anthelmintic 
agents and a huge reason of their failure in resistant helminths. This hallmark affects 
the world economy a great deal. Prodrug strategy is one solution of this major problem 
by targeting drug compounds directly to the site of action by inclusion of a targeting 
moiety. For this purpose, novel amino-colchicines (AM1, AM3, AM4, AM5, AM6) have 
been synthesised that are further conjugated with a TPP targeting moiety to develop 
novel anthelmintic prodrugs (AM2, AM7, AM8, AM9) to achieve selectivity and 
circumvent developing resistance.  TPP is the lipophilic cationic drug delivery vehicle 
that takes the advantage of negative membrane potential of cell and mitochondrial 
membrane and it is highly lipophilic, facilitating both cellular uptake of the drug-TPP 
complex and accumulation in the matrix of mitochondria, hence potentially achieving 
selectivity and bypass of resistance. Novel amino-colchicines hat can disrupt the 
assembly of microtubules, leading to dysfunction of mitochondria and apoptosis in the 
cell. TPP was linked with amino-colchicines with an ester bond that could cleaved by 
an esterase in the worm mitochondria releasing active drug to initiate drug activity. 
The worm viability assay revealed that the TPP-conjugated AM2 prodrug showed 
toxicity towards C. elegans worms that was used as a model organism in this research, 
hence has the potential to be used as an anthelmintic agent in the treatment of 
helminth diseases. Preliminary molecular docking studies also showed that these 
novel amino-colchicines have affinity for tubulin and AM6 showed strong tubulin 
binding with low binding energy of -9.84, indicating strong binding. These novel agents 
have the strong potential to be used as anthelmintic agents in helminth therapy.  
Further work could include inclusion of a true parasite as a model system to check the 
helminth viability and toxic profile of these novel agents towards parasites. 
Technological advancements such as molecular docking can be employed to obtain 
the atomic information of protein-ligand complex interaction has and presented a new 
platform for the drug design and development for the specific targets. It helps to predict 
the best possible interaction between drug molecules and target sites. More work can 
be done on docking studies of TPP conjugates of aminocolchicine (AM2, AM7,AM8 
and AM9) to monitor drug-target interactions and then results can be compared with 
in this area for this purpose. Structural modification can be done to these novel amino-
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colchicines to develop more efficient prodrugs or small molecules that have higher 
potential as anthelmintic agents, for example, further modification at C-10 or C-7 
positions of colchicine ring. Work can be done to check the cytotoxicity of these novel 
agents against cancer cells, preliminary work has already been done on these novel 
drugs using MCF-7 cancer breast carcinoma cell line where they showed some toxicity 























3 Chapter  
                                      3.0 Experimental 
 
 Analytical Methods 
 Thin layer chromatography  
 
Pre-coated aluminium Kieselgel 60 F254 silica plates (Merck) were used for TLC (Thin 
Layer Chromatography). Uncoloured compounds were visualised by UV light (250-
390 nm). Solvent systems used for thin layer chromatography were A) chloroform: 
methanol (CHCl3-MeOH) 4:1; B) chloroform: methanol (CHCl3-MeOH) (9:1, v/v), (C) 
butanol: glacial acetic acid: water (n-Bu-AcOH-H2O) (4:5:1, v/v/v). TLC was used to 
assess compound purity. Compounds were deemed to be pure when observed as 
single spots (homogeneous) by TLC. Percentage yields are reported for the purified 
compounds.  
 
 Column chromatography 
 
Kieselgel 60 (0.063-0.0200 mm) silica gel was used in column chromatography. 
Sometimes a small pump was used to apply air pressure to the column. 
 
 Mass spectrometry 
 
High resolution mass spectrometry-electrospray ionization (HRMS-ESI) were carried 
out using a ThermoFisher LTQ Orbitrap XL or a Waters ZQ4000 instrument. UV-vis 
spectra were measured on a Beckman DU800 spectrophotometer; scan speed 1200 
nm min-1 and wavelength range 400 to 800 nm. Mass spectra were recorded on a 






 Proton and carbon nuclear magnetic resonance (1H and 13C NMR) 
 
1H and 13C NMR were recorded on either a Bruker AC300 or a Bruker AC400 NMR 
spectrometer at 25C at 300.1 MHz and 75.47 MHz, respectively from samples 
dissolved either in deuterated DMSO or deuterated chloroform. In 13C, a DEPT 
(Distortionless Enhancement by Polarization Transfer) experiment was conducted to 
differentiate between quaternary, methylene carbons, methine and methyl carbons 
 
 Chemical reagents 
 
Colchicine 95% dry weight was purchased from Alfa Aesar. All other reagents were 
obtained from Sigma-Aldrich Merck (Gillingham, UK) Purity of compounds was 
assessed as 95 %. 
 
 Synthesis of colchicine-based small molecule compounds (AM 
series): 
 
 Synthesis of Colchicine-Prolinol {N-[10-(2-Hydroxymethyl-pyrrolidin-1-
yl)-1,2,3-trimethoxy-9-oxo-5,6,7,9-tetrahydro-benzo[α]heptalene-7-yl]-
acetamide} (AM1)  
 
To a solution of colchicine (0.25 g, 0.625 mmol) in DMF (1 ml) was added prolinol (168 
µl, 6.26 mmol, 10 eq) at rt After 24 h, the mixture was extracted with CHCl3 and H2O 
(1:1, 100 ml). The combined organic layers were dried over anhydrous Na2SO4, filtered 
and the filterate was concentrated in vacuo. The residue was purified by silica gel 
column chromatography (chloroform: methanol, 9:1 and 4:1). The desired fractions of 
product were combined, filtered, concentrated to dryness under reduced pressure and 
the residue was triturated with ether to give the desired AM1 compound as a yellow 
solid (0.276 g; 94 %).  
TLC (chloroform: methanol, 9: 1) Rf. 0.42.  
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HRMS (ESI+) m/z: 491.21 (14%) (M+Na)+ 470.23 (29%), 469.23 (100%) (M+H)+ . 
Calcd for [C26H32N2O6]+  468.23; found 469.23. 
1H NMR (DMSO-d6, 300 MHz):  (ppm) 1.69-1.90 (m, 3H, C6-CH, N-CH2-CH2), 2.03 
(s, 3H, NH-COCH3), 2.38 (m, 3H, C6-CH, C5-CH2), 3.40-3.50 (m, 2H, N-CH2-CH2-
CH2), 3.64 (s, 3H, C1-OCH3), 3.76 (m, 3H, N-CH2), 3.90 (s, 3H, C3-OCH3), 3.95 (s, 3H, 
C2-OCH3), 4.57 (m, 1H, C7-CH), 6.49 (d, 1H, C11-CH, J 12 Hz), 6.54 (s, 1H, C4-CH), 
7.24 (m, 1H, C8-CH), 7.30 (d, 1H, C12-CH, J 12 Hz), 7.66 (d, 1H, NH-COCH3). 
13C NMR (DMSOd6, 75.5 MHz):  (ppm) 22.46 (+ve, CH2), 22.93 (+ve, C14-CH3), 28.07 
(-ve, CH2), 30.07 (-ve, C5-CH2), 37.35 (-ve, CH2-C6), 50.63 (-ve, CH2), 52.09 (+ve, 
CH-C7), 56.10 (+ve, C3-CH3), 61.28 (+ve, C2-CH3), 61.42 (+ve, C3-CH3), 62.23 (+ve, 
CH), 64.15 (-ve, CH2-OH), 107.41 (+ve, CH-Ar-C4), 113.25 (+ve, C11, CH-Ar), 123.66 
(+ve, CH-Ar, C8), 138.31 (+ve, CH-Ar, C12), 126.22 (absent), 129.85 (absent), 134.72 
(absent), 141.52 (absent), 150.18 (absent), 151.33 (absent), 152.95 (absent), 156.23 
(absent), 176.73 (absent), 169.94 (COO, C13). 
 
 
 Synthesis of Colchicine-Prolinol-TPP {4-[1-(7-Acetylamino-1,2,3-
trimethoxy-9-oxo-5,6,7,9-tetrahydro-benzo[α]heptalene-10-yl)-pyrrolidin-
2-ylmethoxycarbonyl]-butyl}-triphenyl-phosphonium; bromide} (AM2) 
 
To a solution of TPP (0.196 g, 0.442 mmol, 1.3 eq) in dichloromethane (3 ml) was 
added solid colchicine-prolinol (AM1) (0.16 g, 0.341 mmol) and DMAP (25 nano g). To 
this mixture was added DCC (0.105 g, 0.509 mmol, 1.5 eq) in dichloromethane and 
stirred at rt. After 24 h, the mixture was extracted with CHCl3 and H2O (1:1, 100 ml). 
The combined organic layers were dried over anhydrous Na2SO4, filtered and the 
filtrate was concentrated in vacuo. The residue was purified by silica gel column 
chromatography (chloroform: methanol, 9:1 and 4:1). The desired fractions of product 
were combined, filtered, concentrated to dryness under reduced pressure and the 
residue was triturated with ether to give the desired title product colchicine-prolinol-
TPP (AM2) as a yellow solid (0.203 g; 73 %). TLC (chloroform: methanol, 9: 1) Rf. 0.5.   
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HRMS (ESI) m/z: 815.37 (14%) (M+Na)+ , 814.37 (54%), 813.36 (100%) (M+H)+ . 
Calcd for [C49 H54 N2 O7]+  892.29; found 813.36. 
1H NMR (DMSO-d6, 300 MHz):  (ppm) 1.50-1.80 (m, 6H, OCOCH2-CH2-CH2-CH2-P, 
C6-CH), 1.85 (s, 3H, NHCO-CH3), 1.90-1.96 (m, 5H, C6-CH, NCH2-CH2, C5-CH2), 2.17-
2.36 (t, 3H, CH2-CO), 3.47 (s, 3H, C1-OCH3), 3.54 - 3.66 (m, 4H, N-CH2, N-CH2-CH2-
CH2), 3.77 (s, 3H, C3-OCH3), 3.83 (s, 3H, C2-OCH3), 4.34 (m, 1H, C7-CH-NH), 4.99 
(m, 1H, CH-CH2-OCO), 6.50-6.52 (d, 1H, C11-CH, J 11 Hz), 6.72 (s, 1H, C4-CH), 6.84 
(s, 1H, C8-CH), 6.95-6.99 (d, 1H, C12-CH, J 11 Hz), 7.76-7.93 (m, 15H, TPP), 8.48-
8.51 (d, 1H, NH-CO).             
                                                                                                                                                        




To a solution of colchicine (0.25g, 0.625 mmol) in DMF (1 ml) was added 4-
hydroxypiperidine (0.94 g, 9.3 mmol, 15 eq) at rt. After 24 h, the mixture was extracted 
with CHCl3 and H2O (1:1, 100 ml). The combined organic layers were dried over 
anhydrous Na2SO4, filtered and the solvent was concentrated in vacuo. The residue 
was purified by silica gel column chromatography (chloroform: methanol, 9:1 and 4:1). 
The desired fractions of product were combined, filtered, concentrated to dryness 
under reduced pressure and the residue was triturated with ether to give the title 
compound AM3 as a yellow solid (0.261 g; 89 %). TLC (chloroform: methanol, 9: 1). 
Rf. 0.33.  
HRMS (ESI) m/z: 491.2135 (10%) (M+Na)+, 485.2266 (22%), 469.2323 (100 %) 
(M+H)+. Calcd for C26H32N2O6 468.23; Found 469.2323. 
1H NMR (DMSO-d6, 300 MHz):  (ppm) 1.74-1.83 (m, 3H, C6-CH, N-CH2-CH2), 2.03 
(s, 5H, NHCO-CH3, N-CH2-CH2), 2.17 (m, 3H, N-CH2-CH2, C6-CH), 2.45 (m, 2H, C5-
CH2), 3.26 (m, 1H, CH-OH), 3.67 (s, 3H, C1-OCH3), 3.91 OR 3.85-4.05 (s, 8H, C3-
OCH3, C2-OCH3, N-CH2), 4.61-4.69 (m, 1H, C7-CH-NHCOCH3), 6.53 (s, 1H, C4-CH), 




13C NMR (DMSOd6, 75.5 MHz):  (ppm)  22.98 (+ve, C14-CH3), 30.09 (-ve, C5-CH2), 
34.30 (-ve, CH2), 34.39 (-ve, CH2), 36.96 (-ve, CH2-C6), 46.32 (-ve, CH2), 46.45 (-ve, 
CH2), 51.91 (+ve, CH-C7), 56.12 (+ve, C3-CH3), 61.40 (+ve, C2-CH3), 61.44 (+ve, C1-
CH3), 67.41 (+ve, CH), 107.34 (+ve, CH-Ar-C4), 118.17 (+ve, C11, CH-Ar), 128.82 
(+ve, CH-Ar, C8), 136.25 (+ve, CH-Ar, C12), 126.08 (absent), 133.84 (absent), 134.40 
(absent), 141.60 (absent), 149.72 (absent), 151.29 (absent), 153.11 (absent), 158.38 
(absent), 169.89 (absent, C13), 181.32 (COO, C9). 
 
 




To a solution of colchicine (0.25g, 0.626 mmol) in DMF (1 ml) was added (R)-3-
Pyrrolidinol (0.545 g, 6.26 mmol, 10 eq) at room temperature. After 1 h, the mixture 
was extracted with CHCl3 and H2O (1:1, 100 ml). The combined organic layers were 
dried over Na2SO4, filtered and the solvent was concentrated in vacuo. The residue 
was purified by silica gel column chromatography (chloroform: methanol, 9:1 and 4:1). 
The desired fractions of product were combined, filtered, concentrated to dryness 
under reduced pressure at 20 ºC and the residue was triturated with ether to give the 
title compound AM4 as a yellow solid (0.275 g; 96 %). 
 TLC (chloroform: methanol, 9: 1). Rf. 0.19.  
HRMS (ESI) m/z: 457.22 (5%) (M+Na)+, 456.22 (26%), 455.22 (100 %) (M+H)+. Calcd 
for C25H31N2O6 454.21; Found 455.22. 
1H NMR (DMSO-d6, 300 MHz):  (ppm) 1.8 (m, 1H, C6-CH), 2.03 (s, 3H, NHCO-CH3), 
2.07-2.3 (m, 3H, C6-CH and N-CH2-CH2), 2.43 (m, 2H, C5-CH2), 3.65 (s, 3H, C1-OCH3), 
3.78-3.87 (m, 4H, 2 X N-CH2), 3.90 (s, 3H, C3-OCH3), 3.95 (s,3H, C2-OCH3), 4.07 (d, 
1H, CH-OH), 4.55 (m, 1H, CH-OH), 4.6 (m, 1H, C7-CH-NH), 6.41 (d, 1H, C11-CH), 6.52 
(S, 1H, C4-CH), 7.13 (s, 1H, C8-CH), 7.24 (d, 1H, C12-CH). 7.48 (d, 1H, NH-COCH3). 
13C NMR (DMSOd6, 75.5 MHz):  (ppm)  23.02 (+ve, C14-CH3), 30.16 (-ve, C5-CH2), 
33.19 (-ve, CH2), 37.35 (-ve, CH2-C6), 48.61 (-ve, CH2), 51.89 (+ve, CH-C7), 56.12 
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(+ve, C3-CH3), 58.85 (-ve, CH-OH), 61.27 (+ve, C2-CH3), 61.41 (+ve, C1-CH3), 70.40 
(+ve, CH), 107.30 (+ve, CH-Ar-C4), 112.15 (+ve, C11, CH-Ar), 125.19 (+ve, CH-Ar, 
C8), 137.20 (+ve, CH-Ar, C12), 126.57 (absent), 129.10 (absent), 134.55 (absent), 
141.51 (absent), 149.58 (absent), 151.25 (absent), 152.76 (absent), 154.97 (absent), 
169.96 (absent, C13), 178.13 (COO, C9). 
 
 
 Synthesis of Colchicine-(R)-3-(Boc-amino) Pyrrolidine {1-(7-Acetylamino-
1,2,3-trimethoxy-9-oxo-5,6,7,9-tetrahydro-benzo[α]heptalene-10-yl)-
pyrrolidin-3-yl]-carbamic acid ter-butyl ester} (AM5) 
 
To a solution of colchicine (0.25g, 0.626 mmol) in DMF (1 ml) was added (R)-3-(Boc-
amino) Pyrrolidine (0.582 g, 3.13 mmol, 5 eq) at rt and stirred. After 24 h, the mixture 
was extracted with CHCl3 and H2O (1:1, 100 ml). The combined organic layers were 
dried over anhydrous Na2SO4, filtered and the solvent was concentrated in vacuo. The 
residue was purified by silica gel column chromatography (chloroform, chloroform: 
methanol: acetic acid, 9:1: 2 drops). The desired fractions of product were combined, 
filtered, concentrated to dryness under reduced pressure and the residue was 
triturated with ether over an ice bath to give the title compound AM5 as a yellow solid 
(0.310 g, 89 %).  
TLC (chloroform: methanol, 9: 1). Rf. 0.8. 
1H NMR (DMSO-d6, 300 MHz):  (ppm) 1.49 (s, 9H, CH3-BoC), 1.7-1.9 (m, 3H, C6-
CH2, N-CH2-CH2), 2.04 (s, 3H, NHCO-CH3), 2.28 (m, 1H, C6-CH), 2.4 (m, 2H, C5-CH), 
3.6 (s, 3H, C1-OCH3), 3.71-3.88 (m, 4H, 2 x N-CH2), 3.9 (s, 3H, C3-OCH3), 3.96 (s, 3H, 
C2-OCH3), 4.32 (m, 1H,BoC-NH-CH), 4.62 (m, 1H, C7-CH-NHCOCH3), 4.81 (s, 1H, 
CH-NH-BoC), 6.39 (d, 1H, C11-CH, J= 11 Hz), 6.53 (s, 1H, C4-CH), 7.15-7.23 (m, 2H, 
C8-CH, NH-CO-CH), 7.27 (d, 1H, C12-CH, J= 11 Hz). 
13C NMR (DMSOd6, 75.5 MHz):  (ppm)  23.06 (+ve, C14-CH3), 28.40 (+ve, 
CH3x3)Boc), 30.16 (-ve, C5-CH2), 31.42 (-ve, CH2), 37.41 (-ve, CH2-C6), 48.80 (-ve, 
CH2), 51.91 (+ve, CH-C7), 55.89 (-ve, CH2), 56.12 (+ve, C3-CH3), , 61.27 (+ve, C2-
CH3), 61.42 (+ve, C1-CH3), 107.31 (+ve, CH-Ar-C4), 111.73 (+ve, C11, CH-Ar), 
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126.52 (+ve, CH-Ar, C8), 136.97 (+ve, CH-Ar, C12), 129.44 (absent), 134.52 (absent), 
141.59 (absent), 149.70 (absent), 151.36 (absent), 152.80 (absent), 154.79 (absent), 
155.37 (absent, C13), 169.77 (C9), 178.80 (COO, Boc). 
 
 
 Synthesis of AM6 (Col-(R)-3-(amino) Pyrrolidine-TFA) {1-(7-Acetylamino-
1,2,3-trimethoxy-9-oxo-5,6,7,9-tetrahydro-benzo[α]heptalene-10-yl)-
pyrrolidin-3-yl-ammonium; trifluoro-acetate} (AM6) 
 
The Boc protected compound AM5 (Colchicine-(R)-3-(Boc-aminopyrrolidine) (0.28 g, 
0.5 mmol) was treated with TFA (5 ml) for 30 min at rt After 30 min, the mixture was 
concentrated in the presence of ethanol in vacuo, triturated with ether, and filtered to 
give a solid precipitate of desired compound AM6 (0.275 g, 95 %).  
TLC (chloroform: methanol, 9: 1) Rf.  
HRMS (ESI) m/z: 456.2383 (5%) (M+Na)+, 456.2354 (28%), 454.2322 (100 %) 
(M+H)+. Calcd for C27H32N3O7F3 567.22; Found 454.2322. 
 
1H NMR (DMSO-d6, 300 MHz):  (ppm) 1.84 (m, 1H, C6-CH), 1.92-2.07 (m, 3H, NHCO-
CH3), 2.23 (m, 3H, C6-CH, N-CH2-CH2), 2.57 (m, 2H, C5-CH2), 3.51 (s, 3H, C1-OCH3), 
3.7 (m, 2H, C10-N-CH2-CH2), 3.78 (s, 3H, C3-OCH3), 3.82 (s, 3H, C2-OCH3), 3.85-3.98 
(m, 3H, C10-N-CH2-CH and CH-NH3), 4.32 (m, 1H, C7-CH-NHCOCH3), 6.44-646 (d, 
1H, C11-CH,), 6.74 (s, 1H, C4-CH), 6.87 (s, 1H, C8-CH), 7.03-7.07 (d, 1H, C12-CH, J= 
11 Hz), 8.19 (m, 3H, NH3+), 8.54 (d, 1H, NH-COCH3) 
13C NMR (DMSOd6, 75.5 MHz):  (ppm) 22.49 (+ve, CH3-14), 28.39 (-ve, C5-CH2), 
29.48 (-ve, CH2-C4’), 36.48 (-ve, C6-CH2), 47.81 (-ve, CH2-C5’), 49.37 (+ve, C7-CH), 
50.80 (+ve, CH), 53.53 (-ve, CH2), 55.78 (+ve, C3-CH3), 60.52 (+ve, C2-CH3), 60.62 
(+ve, C1-CH3), 107.65 (+ve, CH-Ar-C4), 110.86 (+ve, C11, CH-Ar), 125.50 (+ve, CH-
Ar, C8), 126.14 (absent), 128.43 (absent), 134.40 (absent), 135.94 (+ve, CH-Ar, C12), 
140.69 (absent), 149.25 (absent), 150.44 (absent), 152.32 (absent), 153.67 (absent), 
99 
 
158.09, 158.54 (parts of quaternary form, COOH-CF3, 168.39 (absent, C13, COO), 
177.67 (absent, C-9, COO). 
 
 





To a solution of AM6 (Col-(R)-3-(amino) Pyrrolidine-TFA) (0.150 g, 0.264 mmol) in 
DMF (1 ml) was added TPP (0.198 g, 0.448 mmol, 1.7 eq), PyBOP (0.26 g, 0.501 
mmol, 1.9 eq), HOBt (0.0676 g, 0.501 mmol, 1.9 eq) and DIPEA (0.180 g, 1.39 mmol, 
5.3 eq) in DMF (4 ml). The mixture was stirred at rt. After 24 h, the mixture was 
extracted with CHCl3 and H2O (1:1, 100 ml). The combined organic layers were dried 
over anhydrous Na2SO4, filtered and the solvent was concentrated in vacuo and air 
dried for 1 h. The residue was purified by silica gel column chromatography 
(chloroform, chloroform: methanol, 9:1). The desired fractions of product were 
combined, filtered, concentrated to dryness under reduced pressure and the residue 
was triturated with ether over an ice bath then in the fridge (4 ºC) overnight and vacuum 
dried to give the title compound AM7 (Col-(R)-3-(aminopyrrolidine-TPP) (0.117 g, 50 
%).  
TLC (chloroform: methanol, 4: 1). Rf. 0.91.  
HRMS (ESI) m/z: 800.3699 (15%) (M+Na)+, 799.3667 (52%), 798.3634 (100 %) 
(M+H)+. Calcd for C48H53N3O6PBr 877.29; Found 798.3634. 
1H NMR (DMSO-d6, 300 MHz):  (ppm) 1.50-1.85 (m, 8H, OCOCH2-CH2-CH2-CH2-P, 
NHCO-CH3, C6-CH), 2.01-2.23 (m, 3H, C6-CH, N-CH2-CH2), 2.34 (t, 2H, CH2-C=O), 
2.50 (m, 2H, C5-CH2), 3.02 ( s, 9H, P-CH2), 3.50 (s, 3H, C1-OCH3), 3.60 (m, 2H, C10-
N-CH2-CH2), 3.80 (s, 3H, C3-OCH3), 3.85 (s, 3H, C2-OCH3), 4.20 (m, 3H, C10-N-CH2-
CH, CH-TPP), 4.39 (m, 1H, C7-CH-NHCO), 6.35 (d, 1H, C11-CH, J= 11 Hz), 6.71 (s,1H, 
C4-CH), 6.85 (s, 1H, C8-CH), 7.00 (d, 1H, C12-CH, J= 11 Hz), 7.80 (m, 15H, TPP), 8.15 










To a solution of colchicine-4-hydroxypiperidine (AM3) (0.13 g, 0.277 mmol) in 
dichloromethane (3 ml) was added TPP (0.196 g, 0.443 mmol, 1.6 eq) and DMAP (25 
ng). To this mixture was added DCC (0.105 g, 0.443 mmol, 1.6 eq) in dichloromethane 
and stirred at rt. After 24 h, the mixture was extracted with CHCl3 and H2O (1:1, 100 
ml). The combined organic layers were dried over Na2SO4, filtered and the solvent 
was concentrated in vacuo. The residue was purified by silica gel column 
chromatography (chloroform: methanol, 9:1 and 4:1). The desired fractions of product 
were combined, filtered, concentrated to dryness under reduced pressure and the 
residue was triturated with ether to give desired title product colchicine-4-
hydroxypiperidine-TPP (AM8) as a yellow solid (0.203 g; 90 %).  
TLC (chloroform: methanol, 9: 1) Rf 0.11. HRMS (ESI) m/z: 815.3684 (16%) (M+Na)+ 
, 814.3649 (52%), 813.3620 (100%) (M+H)+ . Calcd for [C49 H54 N2 O7]+  892.29; found 
813.3620. 
 
1H NMR (DMSO-d6, 300 MHz):  (ppm) 1.49-1,63 (m, 8H, OCOCH2-CH2-CH2-CH2-P), 
1.84 (s, 4H, NHCO-CH3 and C6-CH), 2.00-2.04 (m, 2H, N-CH2-CH2), 2.22 (m, 1H, C6-
CH), 2.42 (t, 2H, CH2-C=O), 2.51 (m, 2H, C5-CH2), 3.12-3.25 (m, 3H, N-CH2-CH2), 
3.38-3.43 (m, 2H, CH2-P), 3.52 (s, 3H, C1-OCH3), 3.64 (m, 4H, N-CH2 x 2), 3.78 (s, 
3H, C3-OCH3), 3.83 (s, 3H, C2-OCH3), 4.28-4.36 (m, 1H, CH-OCO), 4.88 (m, 1H, C7-
CH-NH), 6.76 (s, 1H, C4-CH), 6.88 (d, 1H, C11-CH, J=11 Hz), 6.97 (s, 1H, C8-CH), 
7.04-7.08 (d, 1H, C12-CH, J=11 Hz), 7.82 (m, 15H, TPP), 8.56 (d, 1H, NH-COCH3, 
J=7). 
13C NMR (DMSOd6, 75.5 MHz):  (ppm)  22.49 (+ve, C14-CH3), 24.43 (-ve, CH2), 25.30 
(-ve, CH2), 30.35 (-ve, CH2), 32.81 (-ve, CH2), 33.31 (-ve, CH2), 36.11 (-ve, CH2), 
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45.25 (-ve, CH2), 107.70 (+ve, CH-Ar-C4), 117.88 (+ve, C11, CH-Ar), 128.41 (+ve, 
CH-Ar, C8), 130.14-130.31 (ortho, meta, CH-TPP), 133.46-133.60 (ortho, meta, CH-
TPP), 134.33 (+ve, CH-TPP, para), 134.92 (+ve, CH-C12), 140.68 (absent), 149.03 
(absent), 150.44 (absent). 
  
 





To a solution of Colchicine-(R)-3-Pyrrolidinol (AM4) (0.145 g, 0.319 mmol) in 
dichloromethane (3 ml) was added TPP (0.183 g, 0.414 mmol, 1.3eq) and DMAP (25 
ng). To this mixture was added DCC (0.098 g, 0.478 mmol, 1.5 eq) in dichloromethane 
and stirred at rt. After 24 h, the mixture was extracted with CHCl3 and H2O (1:1, 100 
ml). The combined organic layers were dried over anhydrous Na2SO4, filtered and the 
solvent was concentrated in vacuo. The residue was purified by silica gel column 
chromatography (dichloromethane: methanol, 9:1 and 4:1). The desired fractions of 
product were combined, filtered, concentrated to dryness under reduced pressure and 
the residue was triturated with ether to give the desired title product colchicine-(R)-3-
pyrrolidinol-TPP (AM9) as a yellow solid (0.270 g; 96 %).  
TLC (chloroform: methanol, 9: 1). Rf. 0.15.  
 
HRMS (ESI) m/z: 801.3525 (14%) (M+Na)+ , 800.3490 (52%), 799.3461 (100%) 
(M+H)+ . Calcd for [C48 H52 N2 O7]+  878.27; found 799.3461. 
1H NMR (DMSO-d6, 300 MHz):  (ppm) 1.59 (m, 2H, COCH2-CH2-CH2-CH2-P), 1.73 
(m, 2H, OCOCH2-CH2-CH2-CH2-P), 1.85 (s, 4H, NHCO-CH3 and C6-CH), 2.14-2.22 
(m, 3H, C6-CH and N-CH2-CH2), 2.40 (t, 2H, CH2-C=O), 2.51 (m, 2H, C5-CH2), 3.34 
(s, 2H, P-CH2), 3.49 (s, 3H, C1-OCH3), 3.56-3.66 (m, 4H, 2 x N-CH2), 3.78 (s, 3H, C3-
OCH3), 3.83 (s, 4H, C2-OCH3), 4.28-4.37 ( m, 1H C7-CH-NH), 5.27 (s, 1H, CH-OCO), 
6.39-6.43 (d, 1H, C11-CH, J=11 Hz), 6.74 (s, 1H, C4-CH), 6.83 (s, 1H, C8-CH), 6.99-
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7.03 (d, 1H, C12-CH, J= 11 Hz), 7.76 -7.93 (m, 15H, TPP), 8.50-8.52 (d, 1H, NH-
C0CH3). 




• PBS buffer (pH 7.4): 
Phosphate buffer 0.01M,  
Potassium chloride 0.0027 M and  
Sodium chloride 0.137 M), 
• Octanol; 3 mL  
• Quartz cuvette 
• Test samples in DMSO: Colchicine-Prolinol (AM1) (1 mg ml-1; 2134 µM) 
Colchicine-Prolinol-TPP (AM2) (1 mg mL-1; 1227 µM); Colchicine-4-
hydroxypiperidine (AM3) (1 mg ml-1; 2134 µM); Colchicine-(R)-3-Pyrrolidinol 
(AM4) (1 mg ml-1; 2200 µM); Colchicine-(R)-3-(Boc-aminopyrrolidine (AM5) (1 
mg ml-1; 1806 µM); Col-(R)-3-aminopyrrolidine-TFA (AM6) (1 mg ml-1; 1762 
µM); Col-(R)-3-aminopyrrolidine-TPP (AM7) (1 mg ml-1; 1137 µM) Colchicine-
4-hydroxypiperidine-TPP (AM8) (1 mg ml-1; 1118 µM); Colchicine-(R)-3-
Pyrrolidinol-TPP (AM9) (1 mg ml-1; 1136 µM). 
• Beckman DU800 Spectrophotometer. 
 
 Preparation of saturated solutions 
 
PBS buffer (200 mL) was prepared by dissolving a PBS tablet in deionized water. 
Octanol (30 mL) and PBS buffer (30 mL) were combined and shaken for 24 h on a 
vortex. Layers of octanol and PBS buffer were separated in separating funnel. 
  
 Preparation of calibration curves 
 
Stock solutions of the test sample compounds were prepared in DMSO Different 
concentrations of the test compounds were prepared from the 1 mg mL-1 stock 
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solutions by diluting with either octanol saturated phosphate buffer and phosphate 
buffer saturated octanol to concentrations of 5, 10, 15, 20 and 25 µM for each test 
compound. Absorbance values were recorded at the maximum wavelength for each 
compound (between 0 and 0.7) in accordance with the Beer Lambert Law, by using a 
Beckman DU800 Spectrophotometer. Wavelength range and scanning speed were 
set at 320-500 nm and 1200 nm/min respectively. Each experiment was performed in 
triplicate n=3. 
 Distribution coefficient methods 
 
Samples of each compound (1 mg) in triplicate were suspended in octanol (pre-
saturated with PBS for 24 h) (900 µL) and in PBS buffer (pre-saturated with octanol 
for 24 h) (900 µL), mixed by vortex and shaken for 24 h at room temperature until 
dissolved, then the two layers were separated by centrifugation at 2000 g for 5 min. 
Each of the test samples were diluted as follows with either octanol or PBS to give a 
final volume of 3000 µL in a cuvette: for AM1, 30 µL of octanol layer and 800 µL of 
aqueous layer were removed and separately diluted to give 3000 µL (final volume of 
cuvette); for AM2, 30 µL of octanol layer and 400 µL of aqueous layer were removed 
and diluted to 3000µL; for AM3, 30 µL of octanol layer and 300 µL of aqueous layer; 
for AM4, 30 µL of octanol layer and 200 µL of aqueous layer; for AM5, 40 µL of octanol 
and 750 µL of aqueous layer; for AM6, 50 µL of octanol and 50 µL of aqueous layer; 
for AM7, 160 µL of octanol layer and 800 µL of aqueous layer; for AM8, 70 µL of 
octanol layer and 700 µL of aqueous layer and for AM9, 30 µL of octanol and 400 µL 
of aqueous layer. The absorbances were measured at maximum wavelength of 369 
nm (AM1), 372 nm (AM2), 378 nm (AM3), 368 nm (AM4), 368 nm (AM5), 367 nm 
(AM6), 369 nm (AM7), 375 nm (AM8) and 371 nm (AM9) and the calibration curves 
used to determine the concentration in each layer. Distribution coefficients for different 
test compounds were calculated by taking the LOG of the concentration in octanol 




log D oct/water = log
[solute]octanol
[solute]ionised water  + [solute]neutal water
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 Compound Lethality Treatments on C. elegans worms 
 
 Materials and Methods 
 
3.4.1.1 C. elegans maintenance 
C.elegans (wild-type, N2 strain) were obtained from the Caenorhabditis genetics 
centre, University of Minnesota. The C. elegans worms were kept on NGM plates 
seeded with worm food Escherichia coli OP50 at 20 oC in 60 mm or 100 mm diameter 
petri dishes from VWR, UK and Thermo Fischer Scientific, UK respectively. OP50, E. 
coli was obtained from Leibniz Institute DMSZ- German collection of microorganisms 
and cell cultures. The strain of nematodes was maintained by regular transfer of 
nematodes by chunking into fresh NGM plates seeded with OP50. 
C.elegans at L1 and L2 stages were also stored at -80 oC in the freezer by moving 
starved stages (L1 and L2) into vials containing soft agar as freezing solution.  
 
3.4.1.2 Synchronization 
Synchronization protocol as described by Sulston & Hodgkin (1988) was adapted for 
the research work. Mixed culture and synchronized populations were prepared for the 
lethality experiments. L4 stage worms were specifically used for the assays. All the 
treatments were carried out in S medium which is standard liquid medium for the worm 
maintenance. Age specific worms (L4) were maintained at 20 oC in the incubator for 4 
or 24 hours with the food source E. coli OP50. 
 
 Toxic assessment of AM series as novel anthelmintic agents 
 
3.4.2.1 Drug Treatments 
The novel potential anthelmintic agents AM1 (Colchicine-Prolinol) and AM2 (Col-
Prolinol-TPP) were used as the main drugs in the worm lethality assay.  
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 Anthelmintic worm viability assay 
 
A range of different concentrations of colchicine (sigma, Aldrich), AM1 (col-Prolinol), 
AM2 (Col-Prolinol-TPP), TPP, Levamisole from 0 – 100 µM were used for the lethality 
or worm viability assay. Negative control was L stage worms in S medium. DMSO 2%, 
5% was another negative control used and was also the solvent for drug suspensions 
AM1 and AM2. 24-well plates sets were used for the assay containing worms and their 
food was exposed to all the drug treatments in the final volume of 1 ml. The exposure 
time for all the treatments was from 4 h to 24 h at the start then up to 72 h at 20 oC in 
the incubator, performed in staggered time points. Experiments were repeated three 
times, (n= 3). After the incubation time, results were read from samples in the well one 
by one at staggered time points, and percentage survival was calculated and plotted 
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   Structure of AM7: 
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Calibration curves of AM1 (Col-Pro), AM2 (Col-Pro-TPP), AM3 (Col-4-
hydroxypiperidine), AM4 (Col-(R)-3-pyrrolidinol), AM5 (Col-Boc-aminopyrrolidine) and 
AM6 (Col-aminopyrrolidine), AM7 (Col-aminopyrrolidine-TPP), AM8 (Col-4-
hydroxypiperidine-TPP) and AM9 (Col-(R)-3-pyrrolidinol-TPP) plotted by 
octanol/water partition method. 
 

















































Log D calculations for AM1 (Col-Pro), AM2 (Col-Pro-TPP), AM3 (Col-4-
hydroxypiperidine), AM4 (Col-(R)-3-pyrrolidinol), AM5 (Col-Boc-aminopyrrolidine) and 
AM6 (Col-aminopyrrolidine), AM7 (Col-aminopyrrolidine-TPP), AM8 (Col-4-
hydroxypiperidine-TPP) and AM9 (Col-(R)-3-pyrrolidinol-TPP). 
 
Table A. 2.1 Log D values for AM1, calculated from concentration of AM1 in octanol and PBS 






e in cuvette 






in eppendorf  
(M).  
Log D Log D 
Mean 
1 Octanol 0.217 0.217=0.0201x
+0.003 






28.91 1.5 72.27 
2 Octanol 0.1837 0.1837=0.0201
x+0.003 





34.97 1.25 78.69 
3 Octanol 0.2165 0.2165=0.0201
x+0.003 















Table A. 2.2 Log D values for AM2, calculated from concentration of AM2 in octanol and PBS 





























1 Octanol 0.7324 0.7324=0.0237x
-0.003 






34.62 0.25 43.27 










1.357 0.4 1.89 
3 Octanol 0.3158 0.3158=0.0237x
-0.003 





33.81 0.16 39.44 
 
Table A. 2.3 Log D values for AM3, calculated from concentration of AM3 in octanol and PBS 











in eppendorf  
(M).  
Log D Log D 
Mean 
1 Octanol 0.420 0.420=0.0188x
+0.0066 






29.92 2.33 99.74 
2 Octanol 0.4447 0.4447=0.0188
x+0.0066 





26.53 2.33 88.46 
3 Octanol 0.42 0.42=0.0188x+
0.0066 




















Table A. 2.4 Log D values for AM4, calculated from concentration of AM4 in octanol and PBS 














Log D Log D 
Mean 
 
1 Octanol 0.4943 0.4943=0.0337
x+0.0076 






21.34 2.66 78.24 
2 Octanol 0.5857 0.5857=0.0337
x+0.0076 





18.30 4 91.50 
3 Octanol 0.4487 0.4487=0.0337
x+0.0076 






















Table A. 2.5 Log D values for AM5, calculated from concentration of AM5 in octanol and PBS 

















1 Octanol 0.2723 0.2723=0.0293
x+0.0041 






12.21 0 12.21 
2 Octanol 0.64 0.64=0.0293x+
0.0041 





16.26 0 16.26 
3 Octanol 0.6354 0.6354=0.0293
x+0.0041 


















Table A. 2.6 Log D values for AM6, calculated from concentration of AM6 in octanol and PBS 

















1 Octanol 0.2176 0.2176=0.0164
x+0.0081 






30.24 59 1815 
2 Octanol 0.2153 0.2153=0.0164
x+0.0081 





24.43 59 1466.18 
3 Octanol 0.2199 0.2199=0.0164
x+0.0081 






















Table A. 2.7 Log D values for AM7, calculated from concentration of AM7 in octanol and PBS 

















1 Octanol 0.1672 0.1672=0.0101
x+0.0002 






62.15 0 62.15 
2 Octanol 0.375 0.375=0.0101x
+0.0002 





91.35 0.28 117.45 
3 Octanol 0.2287 0.2287=0.0101
x+0.0002 




















Table A. 2.8 Log D values for AM8, calculated from concentration of AM8 in octanol and PBS 

















1 Octanol 0.178 0.178=0.0154x
+0.0006 






40.44 0.42 57.78 
2 Octanol 0.2838 0.2838=0.0154
x+0.0006 





39.05 0.42 55.78 
3 Octanol 0.523 0.523=0.0154x
+0.0006 





















Table A. 2.9 Log D values for AM9, calculated from concentration of AM9 in octanol and PBS 

















1 Octanol 0.2851 0.2851=0.0199
x+0.0059 
14.03 99 1403 1.43 1.37 
 0.04 




37.13 1.5 92.82 
2 Octanol 0.1954 0.1954=0.0199
x+0.0059 





33.56 1.5 83.90 
3 Octanol 0.2162 0.2162=0.0199
x+0.0059 





35.19 1.5 87.97 
 
 
 
 
 
 
 
 
 
